BioMedLib Search Engine [ goto HOMEPAGE ]

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics.

The ability of leukemia cells to accumulate methotrexate polyglutamate (MTXPG) is an important determinant of the antileukemic effects of methotrexate (MTX).

We measured in vivo MTXPG accumulation in leukemia cells from 101 children with acute lymphoblastic leukemia (ALL) and established that B-lineage ALL with either TEL-AML1 or E2A-PBX1 gene fusion, or T-lineage ALL, accumulates significantly lower MTXPG compared with B-lineage ALL without these genetic abnormalities or compared with hyperdiploid (fewer than 50 chromosomes) ALL.

To elucidate mechanisms underlying these differences in MTXPG accumulation, we used oligonucleotide microarrays to analyze expression of 32 folate pathway genes in diagnostic leukemia cells from 197 children.

These findings reveal distinct mechanisms of subtype-specific differences in MTXPG accumulation and point to new strategies to overcome these potential causes of treatment failure in childhood ALL.

Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

MedlinePlus Health Information. consumer health - Folic Acid.

COS Scholar Universe. author profiles.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827850849 for PMID:15630450 [PharmGKB] .

Hazardous Substances Data Bank. METHOTREXATE .

Hazardous Substances Data Bank. FOLIC ACID .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Blood. 2004 Sep 1;104(5):1435-41 [15142881.001]

[Cites] Mol Cell Biochem. 1981 Aug 11;38 Spec No(Pt 1):19-48 [7027025.001]

[Cites] N Engl J Med. 1983 Nov 3;309(18):1094-104 [6353235.001]

[Cites] J Biol Chem. 1985 Aug 15;260(17):9720-6 [2410416.001]

[Cites] Proc Natl Acad Sci U S A. 1985 Aug;82(15):4881-5 [3860829.001]

[Cites] J Clin Invest. 1985 Oct;76(4):1323-9 [2414316.001]

[Cites] Blood. 1990 Jul 1;76(1):117-22 [2364165.001]

[Cites] J Clin Oncol. 1990 Aug;8(8):1380-8 [2380759.001]

[Cites] Math Biosci. 1990 Apr;99(1):105-18 [2134510.001]

[Cites] Blood. 1992 Sep 1;80(5):1158-62 [1381235.001]

[Cites] Blood. 1992 Sep 1;80(5):1316-23 [1381244.001]

[Cites] Blood. 1994 Jul 15;84(2):564-9 [7517720.001]

[Cites] J Clin Oncol. 1994 Aug;12(8):1667-72 [8040679.001]

[Cites] J Clin Invest. 1994 Nov;94(5):1996-2001 [7525652.001]

[Cites] J Clin Invest. 1996 Jan 1;97(1):73-80 [8550853.001]

[Cites] N Engl J Med. 1996 Oct 3;335(14):1041-8 [8793930.001]

[Cites] Blood. 1997 Feb 1;89(3):1013-8 [9028333.001]

[Cites] Cancer Res. 1997 Jun 1;57(11):2193-9 [9187120.001]

[Cites] Mol Pharmacol. 1997 Jul;52(1):155-63 [9224825.001]

[Cites] Cancer Res. 2001 Oct 1;61(19):7225-32 [11585759.001]

[Cites] Ugeskr Laeger. 2008 Jan 28;170(5):328-30 [18252159.001]

[Cites] Biochim Biophys Acta. 2002 Jun 21;1602(2):131-50 [12020800.001]

[Cites] Cancer Res. 2002 Jun 1;62(11):3144-50 [12036927.001]

[Cites] Blood. 2002 Aug 15;100(4):1240-7 [12149204.001]

[Cites] Cancer Res. 2002 Sep 1;62(17):5035-40 [12208758.001]

[Cites] Br J Haematol. 2003 Feb;120(3):484-7 [12580965.001]

[Cites] J Biol Chem. 2003 Feb 28;278(9):6680-6 [12486126.001]

[Cites] Biochem Pharmacol. 2003 Mar 1;65(5):765-71 [12628490.001]

[Cites] Cancer Res. 2003 Sep 1;63(17):5538-43 [14500392.001]

[Cites] Blood. 2003 Oct 15;102(8):2951-9 [12730115.001]

[Cites] JAMA. 2003 Oct 15;290(15):2001-7 [14559953.001]

[Cites] Semin Oncol. 1999 Apr;26(2 Suppl 6):11-23 [10598550.001]

[Cites] Pharmacol Ther. 2000 Mar;85(3):207-15 [10739875.001]

[Cites] Blood. 2000 Jun 1;95(11):3310-22 [10828010.001]

[Cites] J Biol Chem. 2000 Nov 10;275(45):35646-55 [10978335.001]

[Cites] Leukemia. 2000 Dec;14(12):2166-75 [11187907.001]

[Cites] Leukemia. 2001 Jul;15(7):1081-8 [11455977.001]

[Cites] Blood. 1998 Feb 1;91(3):735-46 [9446631.001]

[Cites] Clin Cancer Res. 1998 Sep;4(9):2169-77 [9748136.001]

[Cites] Int J Cancer. 1998 Oct 5;78(2):176-81 [9754649.001]

[Cites] Nat Genet. 1999 Jan;21(1 Suppl):20-4 [9915496.001]

[Cites] Leuk Lymphoma. 1998 Nov;31(5-6):507-19 [9922041.001]

[Cites] Blood. 1999 Mar 1;93(5):1643-50 [10029593.001]

[Cites] Blood. 1999 Mar 1;93(5):1677-83 [10029597.001]

[Cites] Cancer Res. 1999 Jun 1;59(11):2532-5 [10363967.001]

[Cites] Methods Mol Biol. 2002;184:143-68 [11889711.001]

[Cites] Oncogene. 2003 Oct 20;22(47):7431-57 [14576850.001]

[Cites] Clin Cancer Res. 2003 Nov 1;9(14):5171-7 [14613996.001]

[Cites] Biochem Pharmacol. 2004 Apr 15;67(8):1541-8 [15041471.001]

[Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]

[Cites] Pharmacogenetics. 2004 Aug;14(8):557-67 [15284538.001]

(PMID = 15630450.001).

[ISSN] 0021-9738

[Journal-full-title] The Journal of clinical investigation

[ISO-abbreviation] J. Clin. Invest.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / R01 CA71907-07; United States / NCI NIH HHS / CA / R37 CA36401; United States / NCI NIH HHS / CA / P01 CA071907; United States / NIGMS NIH HHS / GM / U01 GM061393; United States / NCI NIH HHS / CA / R01 CA078224; United States / NCI NIH HHS / CA / R37 CA036401; United States / NCI NIH HHS / CA / CA21765; United States / NIGMS NIH HHS / GM / U01 GM61393; United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / R01 CA051001; United States / NCI NIH HHS / CA / R01 CA78224; United States / NCI NIH HHS / CA / R01 CA51001

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.

[Publication-country] United States

[Chemical-registry-number] 0 / RNA, Messenger; 25513-46-6 / Polyglutamic Acid; 82334-40-5 / methotrexate polyglutamate; 9007-49-2 / DNA; 935E97BOY8 / Folic Acid; EC 2.1.1.45 / Thymidylate Synthase; YL5FZ2Y5U1 / Methotrexate

[Other-IDs] NLM/ PMC539195

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Homozygous deletion of CDKN2A (p16, p14) and CDKN2B (p15) genes is a poor prognostic factor in adult but not in childhood B-lineage acute lymphoblastic leukemia: a comparative deletion and hypermethylation study.

The biological behavior of childhood B-lineage acute lymphoblastic leukemia (B-ALL) is different from that of adults.

[MeSH-major] Cyclin-Dependent Kinase Inhibitor p15 / genetics. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Gene Deletion. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics

Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19837270.001).

[ISSN] 1873-4456

[Journal-full-title] Cancer genetics and cytogenetics

[ISO-abbreviation] Cancer Genet. Cytogenet.

[Language] eng

[Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / CDKN2B protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p15; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Oncogene Proteins, Fusion

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected].

PURPOSE: Treatment of childhood relapsed acute lymphoblastic leukemia (ALL) remains a significant challenge.

Five of seven patients with T-cell ALL (T-ALL) failed to achieve CR2.

CONCLUSION: The AALL01P2 regimen is a tolerable and active reinduction platform, suitable for testing in combination with novel agents in B-precursor ALL.

Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. CYTARABINE .

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. DEXAMETHASONE .

Hazardous Substances Data Bank. PREDNISONE .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Blood. 2000 Sep 1;96(5):1709-15 [10961868.001]

[Cites] Med Pediatr Oncol. 2000 May;34(5):313-8 [10797352.001]

[Cites] Lancet. 2001 Oct 13;358(9289):1239-41 [11675066.001]

[Cites] Br J Haematol. 2002 Sep;118(3):741-7 [12181040.001]

[Cites] Leukemia. 2002 Sep;16(9):1668-72 [12200679.001]

[Cites] Leukemia. 2003 Aug;17(8):1566-72 [12886244.001]

[Cites] Br J Haematol. 2003 Nov;123(3):396-405 [14616997.001]

[Cites] Leukemia. 2004 Mar;18(3):499-504 [14981525.001]

[Cites] Br J Cancer. 1977 Jan;35(1):1-39 [831755.001]

[Cites] Cancer. 1980 Jun 15;45(12):3090-4 [6930318.001]

[Cites] J Clin Oncol. 1985 Jul;3(7):998-1004 [3860629.001]

[Cites] Blood. 1988 Oct;72(4):1286-92 [3167209.001]

[Cites] Blood. 1991 Sep 1;78(5):1166-72 [1878583.001]

[Cites] Blood. 1993 Feb 1;81(3):602-9 [8427957.001]

[Cites] Med Pediatr Oncol. 1993;21(7):470-6 [8341213.001]

[Cites] J Pediatr Hematol Oncol. 1995 Feb;17(1):34-8 [7743235.001]

[Cites] Med Pediatr Oncol. 1995 Nov;25(5):372-8 [7674994.001]

[Cites] Blood. 1996 Aug 1;88(3):831-7 [8704238.001]

[Cites] Med Pediatr Oncol. 1996 Dec;27(6):505-14 [8888809.001]

[Cites] Br J Haematol. 1997 Dec;99(3):671-7 [9401083.001]

[Cites] Blood. 1998 Dec 1;92(11):4072-9 [9834212.001]

[Cites] Cancer. 2005 Jan 15;103(2):368-76 [15599932.001]

[Cites] Br J Haematol. 2005 Jul;130(1):67-75 [15982346.001]

[Cites] J Clin Oncol. 2005 Nov 1;23(31):7942-50 [16258094.001]

[Cites] J Clin Oncol. 2006 Jul 1;24(19):3150-6 [16717292.001]

[Cites] Blood. 2006 Jul 15;108(2):711-7 [16822902.001]

[Cites] J Clin Oncol. 2006 Dec 20;24(36):5750-62 [17179109.001]

[Cites] Blood. 2008 Jun 15;111(12):5477-85 [18388178.001]

[Cites] J Clin Oncol. 2008 Aug 1;26(22):3756-62 [18669463.001]

[Cites] Pediatr Blood Cancer. 2004 Oct;43(5):571-9 [15382275.001]

[Cites] Haematologica. 2000 Nov;85(11 Suppl):47-53 [11268324.001]

[Cites] Br J Haematol. 2000 Mar;108(3):531-43 [10759711.001]

[ErratumIn] J Clin Oncol. 2008 Oct 1;26(28): 4697.

(PMID = 18711187.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / R21CA110344; United States / NCI NIH HHS / CA / U10 CA98543

[Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural

[Publication-country] United States

[Chemical-registry-number] 04079A1RDZ / Cytarabine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; VB0R961HZT / Prednisone; ZRP63D75JW / Idarubicin

[Other-IDs] NLM/ PMC2654313

   

Advertisement

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Are survivors of acute lymphoblastic leukemia (ALL) at increased risk of cardiovascular disease?

Through a variety of different mechanisms, it appears that survivors of childhood acute lymphoblastic leukemia have an increased prevalence of several cardiovascular risk factors and thus are at increased risk for developing cardiovascular disease.

The aim of this paper is to describe the current understanding of particular risk factors, including obesity, physical inactivity, dyslipidemia, insulin resistance, and metabolic syndrome, that may contribute to cardiovascular disease in survivors of childhood ALL.

Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] (c) 2007 Wiley-Liss, Inc.

(PMID = 18064658.001).

[ISSN] 1545-5017

[Journal-full-title] Pediatric blood & cancer

[ISO-abbreviation] Pediatr Blood Cancer

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / CA100474-04; United States / NCI NIH HHS / CA / R01 CA100474; United States / NCI NIH HHS / CA / R01 CA100474-04; United States / NCI NIH HHS / CA / R01-CA-100474

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review

[Publication-country] United States

[Number-of-references] 57

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR.

Minimal (i.e. submicroscopic) residual disease (MRD) predicts outcome in childhood acute lymphoblastic leukaemia (ALL).

[MeSH-major] Biomarkers, Tumor / analysis. Flow Cytometry / methods. Polymerase Chain Reaction / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15755280.001).

[ISSN] 0007-1048

[Journal-full-title] British journal of haematology

[ISO-abbreviation] Br. J. Haematol.

[Language] eng

[Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Biomarkers, Tumor

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [The clinical significance of detecting minimal residual disease in acute childhood B-cell lymphoblastic leukemia with flow cytometry].

OBJECTIVE: Flow cytometry may be used to detect minimal residual disease (MRD) in acute lymphoblastic leukemia because leukemic cells often display aberrant phenotypes when compared to normal cells.

The investigators also aimed to study the value of the detection of MRD by flow cytometry in childhood B-ALL without effective antibody combinations.

METHODS: Thirty-six cases of childhood B-ALL with effective antibody combinations were performed MRD analysis after induction therapy.

(1) Forty-two cases of childhood B-ALL were screened for antibody combinations of interest and were identified in 86% (36/42) of the cases.

CONCLUSION:. (1) Flow cytometry is a sensitive and specific method for detecting MRD of childhood ALL, and could predict the coming relapse. (2) Patients with MRD levels > 10(-3) had poor prognosis. (3) The levels of MRD at month 9 and 12 had prognostic value. (4) The value of antibody combinations consisting of CD(45)/CD(19)/CD(10)/CD(34) and CD(45)/CD(19)/CD(20)/CD(22) should be further investigated in patients without effective antibody combinations.

[MeSH-major] B-Lymphocyte Subsets / immunology. Flow Cytometry. Immunophenotyping. Neoplasm, Residual / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16083543.001).

[ISSN] 0578-1310

[Journal-full-title] Zhonghua er ke za zhi = Chinese journal of pediatrics

[ISO-abbreviation] Zhonghua Er Ke Za Zhi

[Language] chi

[Publication-type] English Abstract; Evaluation Studies; Journal Article

[Publication-country] China

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

It is an essential trace element, critical for cell growth, development and differentiation, DNA synthesis, RNA transcription, cell division, and cell activation.

Zinc deficiency has adverse consequences during embryogenesis and early childhood development, particularly on immune functioning.

Zinc depletion induces cell death via apoptosis (or necrosis if apoptotic pathways are blocked) while sufficient zinc levels allows maintenance of autophagy.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. ZINC, ELEMENTAL .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Int Rev Neurobiol. 1989;31:145-238 [2689380.001]

[Cites] Free Radic Biol Med. 1990;9(3):229-33 [2272531.001]

[Cites] Biochem Int. 1991 Aug;24(6):1093-101 [1781788.001]

[Cites] Int J Cancer. 1992 Oct 21;52(4):604-8 [1328072.001]

[Cites] Physiol Rev. 1993 Jan;73(1):79-118 [8419966.001]

[Cites] Biochem J. 1993 Dec 1;296 ( Pt 2):403-8 [8257431.001]

[Cites] Science. 1995 Mar 10;267(5203):1456-62 [7878464.001]

[Cites] J Nutr. 1995 Apr;125(4):823-9 [7722683.001]

[Cites] Nutrition. 1995 Jan-Feb;11(1 Suppl):93-9 [7749260.001]

[Cites] Kokubyo Gakkai Zasshi. 1995 Mar;62(1):78-93 [7751801.001]

[Cites] Ann Clin Lab Sci. 1995 Mar-Apr;25(2):134-42 [7785963.001]

[Cites] Neurochem Int. 1995 Jul;27(1):23-33 [7655345.001]

[Cites] J Immunol. 1995 Nov 1;155(9):4143-6 [7594568.001]

[Cites] Teratology. 1995 Sep;52(3):149-59 [8638255.001]

[Cites] Proc Natl Acad Sci U S A. 1996 Mar 19;93(6):2454-8 [8637895.001]

[Cites] Proc Natl Acad Sci U S A. 1996 May 28;93(11):5624-8 [8643627.001]

[Cites] Nature. 2004 Dec 23;432(7020):1032-6 [15525940.001]

[Cites] Cell Calcium. 2005 Mar;37(3):225-32 [15670869.001]

[Cites] Cell. 2005 Jan 28;120(2):159-62 [15680321.001]

[Cites] Nat Rev Immunol. 2005 Apr;5(4):331-42 [15803152.001]

[Cites] Biochem Biophys Res Commun. 2005 Sep 16;335(1):162-7 [16055081.001]

[Cites] J Surg Oncol. 2005 Sep 1;91(3):204-8 [16118778.001]

[Cites] J Immunol. 2005 Oct 1;175(7):4697-705 [16177117.001]

[Cites] Trends Cell Biol. 1999 Dec;9(12):M49-52 [10611682.001]

[Cites] Am J Clin Nutr. 2000 Jan;71(1):81-7 [10617950.001]

[Cites] Nat Cell Biol. 2000 Feb;2(2):76-83 [10655586.001]

[Cites] J Nutr. 2000 May;130(5):1085-8 [10801901.001]

[Cites] J Nutr. 2000 May;130(5S Suppl):1399S-406S [10801951.001]

[Cites] J Nutr. 2000 May;130(5S Suppl):1459S-66S [10801960.001]

[Cites] Eur J Biochem. 2000 Jun;267(12):3469-76 [10848962.001]

[Cites] J Infect Dis. 2000 Sep;182 Suppl 1:S62-8 [10944485.001]

[Cites] J Pharmacol Exp Ther. 2000 Sep;294(3):997-1008 [10945852.001]

[Cites] Annu Rev Biochem. 2000;69:217-45 [10966458.001]

[Cites] Cell. 2000 Sep 1;102(5):549-52 [11007473.001]

[Cites] J Infect Dis. 2000 Sep;182 Suppl 1:S85-92 [11041715.001]

[Cites] Am J Clin Nutr. 2000 Dec;72(6):1516-22 [11101480.001]

[Cites] Proc Nutr Soc. 2000 Nov;59(4):541-52 [11115789.001]

[Cites] Biochem Biophys Res Commun. 2000 Dec 20;279(2):607-14 [11118333.001]

[Cites] J Biochem. 2000 Dec;128(6):933-9 [11098135.001]

[Cites] Immunity. 2001 Jan;14(1):93-104 [11163233.001]

[Cites] Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1734-9 [11172020.001]

[Cites] J Am Diet Assoc. 2001 Mar;101(3):294-301 [11269606.001]

[Cites] Biochem Biophys Res Commun. 2001 Apr 13;282(4):1067-73 [11352661.001]

[Cites] J Biol Chem. 2001 Jun 22;276(25):22258-64 [11301334.001]

[Cites] J Lab Clin Med. 2001 Oct;138(4):250-6 [11574819.001]

[Cites] J Neurophysiol. 2001 Nov;86(5):2597-604 [11698545.001]

[Cites] Biometals. 2001 Sep-Dec;14(3-4):315-30 [11831462.001]

[Cites] J Nutr. 2002 May;132(5):974-9 [11983824.001]

[Cites] Am J Clin Nutr. 2002 Jun;75(6):1062-71 [12036814.001]

[Cites] J Biol Chem. 2002 Oct 18;277(42):39209-16 [12161443.001]

[Cites] Eukaryot Cell. 2002 Feb;1(1):11-21 [12455967.001]

[Cites] Biochem Biophys Res Commun. 2003 Apr 4;303(2):586-93 [12659860.001]

[Cites] Mech Ageing Dev. 2003 Apr;124(4):459-68 [12714254.001]

[Cites] J Nutr. 2003 May;133(5 Suppl 1):1452S-6S [12730441.001]

[Cites] FEMS Microbiol Rev. 2003 Jun;27(2-3):291-311 [12829272.001]

[Cites] Mol Med. 2003 Mar-Apr;9(3-4):65-76 [12865942.001]

[Cites] Am J Physiol Endocrinol Metab. 2003 Nov;285(5):E1095-102 [12812920.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12301-6 [14530385.001]

[Cites] Nat Immunol. 2003 Dec;4(12):1164-5 [14639465.001]

[Cites] Cell Mol Life Sci. 2004 Jan;61(1):49-68 [14704853.001]

[Cites] Pflugers Arch. 2004 Feb;447(5):744-51 [12748859.001]

[Cites] Pflugers Arch. 2004 Feb;447(5):796-800 [12748861.001]

[Cites] Mol Biol Cell. 2004 Mar;15(3):1101-11 [14699058.001]

[Cites] Cell Immunol. 1979 Sep 15;47(1):100-5 [509529.001]

[Cites] J Immunol. 1980 Jun;124(6):2650-5 [6966295.001]

[Cites] Cancer. 1981 Apr 1;47(7):1845-8 [7226079.001]

[Cites] Int J Biochem. 1982;14(11):983-90 [7141075.001]

[Cites] Cancer. 1983 Sep 1;52(5):868-72 [6871828.001]

[Cites] Eur J Immunol. 1984 May;14(5):454-8 [6609827.001]

[Cites] J Lab Clin Med. 1985 Jan;105(1):19-22 [3968462.001]

[Cites] J Pharmacol. 1985 Oct-Dec;16(4):344-52 [2419703.001]

[Cites] Cell Death Differ. 2001 Mar;8(3):265-72 [11319609.001]

[Cites] Neoplasma. 1986;33(1):85-90 [3960212.001]

[Cites] J Clin Invest. 1988 Oct;82(4):1202-10 [3262625.001]

[Cites] Biochem J. 2006 Feb 15;394(Pt 1):275-83 [16236025.001]

[Cites] Eur J Immunol. 2006 Feb;36(2):421-30 [16402406.001]

[Cites] Biogerontology. 2005 Dec;6(6):407-13 [16518702.001]

[Cites] J Trace Elem Med Biol. 2006;20(1):3-18 [16632171.001]

[Cites] Curr Opin Pharmacol. 2006 Jun;6(3):237-43 [16540372.001]

[Cites] Mol Cancer. 2006;5:17 [16700911.001]

[Cites] J Immunol. 2006 Jul 15;177(2):1296-305 [16818790.001]

[Cites] J Biol Chem. 2006 Aug 25;281(34):24085-9 [16793761.001]

[Cites] Nat Immunol. 2006 Sep;7(9):971-7 [16892068.001]

[Cites] Toxicol Lett. 2006 Oct 25;166(3):222-8 [16930873.001]

[Cites] Oncogene. 2006 Oct 30;25(51):6680-4 [17072321.001]

[Cites] Biogerontology. 2006 Oct-Dec;7(5-6):357-65 [16955215.001]

[Cites] J Biol Inorg Chem. 2006 Nov;11(8):1049-62 [16924557.001]

[Cites] Exp Gerontol. 2006 Nov;41(11):1094-107 [17030107.001]

[Cites] Transl Res. 2006 Dec;148(6):325-33 [17162254.001]

[Cites] ACS Chem Biol. 2006 Mar 17;1(2):103-11 [17163650.001]

[Cites] J Mol Biol. 2007 Feb 2;365(5):1417-28 [17118402.001]

[Cites] Acta Physiol Hung. 1989;74(2):195-9 [2603734.001]

[Cites] Biochem Soc Trans. 1990 Apr;18(2):299-301 [2379727.001]

[Cites] Mol Cancer. 2007;6:37 [17550612.001]

[Cites] Anticancer Res. 2007 Jul-Aug;27(4A):1941-3 [17649800.001]

[Cites] J Immunol. 2007 Sep 15;179(6):4180-6 [17785857.001]

[Cites] J Neurosci Res. 2007 Oct;85(13):2844-55 [17628505.001]

[Cites] Eur J Dermatol. 2007 Nov-Dec;17(6):492-6 [17951128.001]

[Cites] Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18636-41 [18003899.001]

[Cites] Int J Radiat Oncol Biol Phys. 2008 Feb 1;70(2):368-73 [17980503.001]

[Cites] Mol Immunol. 2008 Mar;45(6):1633-45 [18207244.001]

[Cites] J Neurosci. 2008 Mar 19;28(12):3114-22 [18354014.001]

[Cites] Int J Dermatol. 2008 Apr;47(4):372-3 [18377601.001]

[Cites] Exp Gerontol. 2008 May;43(5):488-92 [18068923.001]

[Cites] Exp Gerontol. 2008 May;43(5):462-71 [18215484.001]

[Cites] Exp Gerontol. 2008 May;43(5):452-61 [18304769.001]

[Cites] Am J Clin Nutr. 2008 May;87(5):1530-4 [18469280.001]

[Cites] Biometals. 2008 Aug;21(4):405-16 [18097638.001]

[Cites] Nat Immunol. 2008 Sep;9(9):1055-64 [18660811.001]

[Cites] Toxicol Appl Pharmacol. 2008 Sep 1;231(2):260-6 [18513776.001]

[Cites] Neuropharmacology. 1996 May;35(5):599-603 [8887968.001]

[Cites] Proc Assoc Am Physicians. 1997 Jan;109(1):68-77 [9010918.001]

[Cites] Brain Res. 1996 Dec 16;743(1-2):362-5 [9017270.001]

[Cites] J Nutr. 1997 Jul;127(7):1290-6 [9202082.001]

[Cites] Am J Physiol. 1997 Jun;272(6 Pt 1):E1002-7 [9227444.001]

[Cites] Nat Struct Biol. 1997 Aug;4(8):635-43 [9253413.001]

[Cites] Cornea. 1997 Sep;16(5):550-5 [9294688.001]

[Cites] Br Med Bull. 1997;53(3):451-65 [9374030.001]

[Cites] Immunol Today. 1997 Nov;18(11):519-21 [9386346.001]

[Cites] J Am Coll Nutr. 1998 Dec;17(6):556-63 [9853534.001]

[Cites] J Biol Chem. 1999 Feb 19;274(8):5053-60 [9988752.001]

[Cites] Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2414-9 [10051656.001]

[Cites] Clin Exp Immunol. 1999 Apr;116(1):19-27 [10209500.001]

[Cites] Cancer Res. 1999 Jun 15;59(12):2838-42 [10383143.001]

[Cites] Nat Rev Mol Cell Biol. 2004 Nov;5(11):920-31 [15520811.001]

[Cites] Am J Med. 1961 Oct;31:532-46 [14488490.001]

[Cites] Science. 2004 Nov 5;306(5698):990-5 [15528435.001]

[Cites] J Leukoc Biol. 2009 Aug;86(2):337-48 [19401385.001]

[Cites] Biogerontology. 2009 Oct;10(5):593-604 [19043799.001]

[Cites] Curr Opin Clin Nutr Metab Care. 2009 Nov;12(6):646-52 [19710611.001]

[Cites] Neurotox Res. 2010 Jan;17(1):1-14 [19784710.001]

[Cites] Biochim Biophys Acta. 2010 Jan-Feb;1799(1-2):131-40 [20123075.001]

[Cites] Immunity. 2010 Feb 26;32(2):227-39 [20171125.001]

[Cites] Toxicol Appl Pharmacol. 2010 Mar 15;243(3):405-19 [20043934.001]

[Cites] Int J Epidemiol. 2010 Apr;39 Suppl 1:i63-9 [20348128.001]

[Cites] J Nutr. 2010 May;140(5):1049-56 [20237063.001]

[Cites] Int Immunol. 2010 May;22(5):375-86 [20215335.001]

[Cites] Eur J Immunol. 2010 May;40(5):1496-503 [20201035.001]

[Cites] Mol Immunol. 2010 Jun;47(10):1882-9 [20417561.001]

[Cites] Am J Physiol Lung Cell Mol Physiol. 2010 Jun;298(6):L744-54 [20207754.001]

[Cites] Exp Biol Med (Maywood). 2010 Jun;235(6):741-50 [20511678.001]

[Cites] Int J Epidemiol. 2010 Jun;39(3):795-808 [20156999.001]

[Cites] Glia. 2010 Aug;58(10):1186-96 [20544854.001]

[Cites] Mol Cell Biol. 2010 Aug;30(16):3929-42 [20547752.001]

[Cites] J Leukoc Biol. 2010 Sep;88(3):589-96 [20551211.001]

[Cites] Apoptosis. 2010 Oct;15(10):1177-86 [20567904.001]

[Cites] Biometals. 2010 Dec;23(6):997-1013 [20524045.001]

[Cites] Biochim Biophys Acta. 2010 Oct-Dec;1799(10-12):717-25 [20594930.001]

[Cites] J Nutr Biochem. 2011 Jan;22(1):79-88 [20392624.001]

[Cites] Biometals. 2009 Dec;22(6):1031-40 [19609684.001]

[Cites] Cell Death Differ. 2005 Nov;12 Suppl 2:1542-52 [16247502.001]

[Cites] J Nutr. 2001 Dec;131(12):3189-96 [11739864.001]

[Cites] Am J Clin Nutr. 2002 Feb;75(2):300-7 [11815322.001]

[Cites] Cancer Sci. 2007 May;98(5):692-7 [17359283.001]

[Cites] J Cell Biol. 2007 May 21;177(4):637-45 [17502426.001]

[Cites] Nat Rev Microbiol. 2004 Apr;2(4):301-14 [15031729.001]

[Cites] Dev Cell. 2004 Apr;6(4):463-77 [15068787.001]

[Cites] Trends Cell Biol. 2004 Feb;14(2):70-7 [15102438.001]

[Cites] Am J Pathol. 2004 May;164(5):1547-56 [15111301.001]

[Cites] J Biol Chem. 2004 May 21;279(21):21976-83 [15028711.001]

[Cites] Nature. 2004 May 20;429(6989):298-302 [15129296.001]

[Cites] Annu Rev Nutr. 2004;24:151-72 [15189117.001]

[Cites] Annu Rev Nutr. 2004;24:277-98 [15189122.001]

[Cites] Exp Cell Res. 2004 Aug 1;298(1):229-38 [15242777.001]

[Cites] J UOEH. 2004 Jun 1;26(2):193-205 [15244072.001]

[Cites] Int J Biochem Cell Biol. 2004 Dec;36(12):2420-34 [15325582.001]

[Cites] Int J Biochem Cell Biol. 2004 Dec;36(12):2435-44 [15325583.001]

[Cites] FEMS Yeast Res. 2004 Nov;5(2):101-10 [15489192.001]

[Cites] J Natl Cancer Inst. 1971 Jul;47(1):1-13 [4328191.001]

[Cites] Cancer Res. 1975 Nov;35(11 Pt. 2):3481-7 [1104155.001]

[Cites] Langenbecks Arch Chir. 1978 Aug 18;346(2):129-33 [682772.001]

[Cites] J Nutr. 1979 Nov;109(11):1847-55 [315453.001]

[Cites] Cancer Sci. 2008 Aug;99(8):1515-22 [18754861.001]

[Cites] Endocrinology. 2008 Oct;149(10):4912-20 [18583420.001]

[Cites] J Am Coll Nutr. 2008 Oct;27(5):577-87 [18845708.001]

[Cites] J Immunol. 2008 Nov 1;181(9):6491-502 [18941240.001]

[Cites] Biochem Soc Trans. 2008 Dec;36(Pt 6):1247-51 [19021534.001]

[Cites] Methods Enzymol. 2008;450:287-309 [19152866.001]

[Cites] Biometals. 2009 Feb;22(1):149-57 [19130267.001]

[Cites] Nutr Cancer. 2009;61(2):206-15 [19235036.001]

[Cites] Toxicol Appl Pharmacol. 2009 Mar 1;235(2):163-70 [19063910.001]

[Cites] Trends Mol Med. 2009 Mar;15(3):101-11 [19246244.001]

[Cites] Crit Care Med. 2009 Apr;37(4):1380-8 [19242332.001]

[Cites] J Cell Biochem. 2009 Apr 1;106(5):750-7 [19160419.001]

[Cites] J Mol Biol. 2009 Apr 24;388(1):144-58 [19281821.001]

[Cites] J Transl Med. 2009;7:17 [19292913.001]

[Cites] J Clin Immunol. 2009 Jul;29(4):416-25 [19408107.001]

[Cites] Glia. 2009 Sep;57(12):1351-61 [19229997.001]

[Cites] Annu Rev Nutr. 2009;29:153-76 [19400752.001]

(PMID = 21087493.001).

[ISSN] 1479-5876

[Journal-full-title] Journal of translational medicine

[ISO-abbreviation] J Transl Med

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / P01 CA 10944-04

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review

[Publication-country] England

[Chemical-registry-number] J41CSQ7QDS / Zinc

[Other-IDs] NLM/ PMC3002329

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Epidemiological studies of IBS point to risk factors such as familial clustering, sexual abuse and other forms of childhood trauma, low birth weight and gastrointestinal infection.

Studies in animal models of early stress and in humans who have experienced childhood trauma or abuse suggest that these events can lead to long-lasting epigenetic changes in the glucocorticoid receptor gene brought about by hypermethylation of a key regulatory component.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Ann Neurol. 2008 Dec;64(6):602-17 [19107999.001]

[Cites] Biol Psychiatry. 2009 Feb 1;65(3):263-7 [18723164.001]

[Cites] World J Gastroenterol. 2008 Nov 21;14(43):6636-40 [19034965.001]

[Cites] PLoS One. 2008 May 07;3(5):e2085 [18461137.001]

[Cites] Am J Gastroenterol. 2010 Feb;105(2):275-9 [20068561.001]

[Cites] Gut. 2006 Dec;55(12):1754-9 [17008364.001]

[Cites] Schizophr Bull. 1976;2(3):360-401 [1034336.001]

[Cites] J Gastroenterol Hepatol. 2010 Apr;25(4):691-9 [20074154.001]

[Cites] Am J Clin Nutr. 2007 May;85(5):1417-27 [17490981.001]

[Cites] Psychosom Med. 1998 May-Jun;60(3):258-67 [9625212.001]

[Cites] BMC Gastroenterol. 2009 Jan 20;9:6 [19154614.001]

[Cites] J Trauma Stress. 2009 Oct;22(5):427-34 [19813242.001]

[Cites] Scand J Gastroenterol Suppl. 2003;(237):1-8 [12797672.001]

[Cites] J Psychiatr Res. 2008 Oct;42(13):1104-11 [18281061.001]

[Cites] Trends Mol Med. 2007 Jul;13(7):269-77 [17544850.001]

[Cites] J Clin Psychiatry. 2001;62 Suppl 8:38-45; discussion 46-7 [12108820.001]

[Cites] PLoS Pathog. 2008 Aug 01;4(8):e1000112 [18670628.001]

[Cites] Science. 2008 Mar 28;319(5871):1785-6 [18369135.001]

[Cites] Gut. 2003 Dec;52(12):1703-7 [14633946.001]

[Cites] Prog Neurobiol. 2008 Dec 11;86(4):305-41 [18940229.001]

[Cites] Am J Psychiatry. 1993 Oct;150(10):1502-6 [8379554.001]

[Cites] Eur J Hum Genet. 2007 Jul;15(7):784-90 [17457370.001]

[Cites] Gastroenterology. 2005 Mar;128(3):541-51 [15765388.001]

[Cites] Rev Endocr Metab Disord. 2007 Jun;8(2):173-82 [17638084.001]

[Cites] Trends Mol Med. 2009 Oct;15(10):478-89 [19811951.001]

[Cites] Lancet. 2001 Dec 15;358(9298):2061-8 [11755632.001]

[Cites] Nat Neurosci. 2009 Dec;12(12):1559-66 [19898468.001]

[Cites] Eur J Gastroenterol Hepatol. 1997 Apr;9(4):345-52 [9160196.001]

[Cites] Hum Mol Genet. 2008 Oct 1;17 (19):2967-77 [18614545.001]

[Cites] Gut. 2004 Jun;53(6):829-37 [15138209.001]

[Cites] Gastroenterology. 2001 Oct;121(4):799-804 [11606493.001]

[Cites] Cell. 1993 Dec 3;75(5):843-54 [8252621.001]

[Cites] Gut. 2004 Oct;53(10):1452-8 [15361494.001]

[Cites] Gastroenterology. 2006 Feb;130(2):304-11 [16472586.001]

[Cites] Int J Neuropsychopharmacol. 2010 Apr;13(3):395-404 [19849891.001]

[Cites] Dig Dis Sci. 2009 Nov;54(11):2318-24 [19655247.001]

[Cites] Aliment Pharmacol Ther. 2003 Mar 1;17(5):643-50 [12641512.001]

[Cites] Am J Gastroenterol. 1998 Aug;93(8):1311-7 [9707057.001]

[Cites] Physiol Rev. 2007 Jul;87(3):799-823 [17615389.001]

[Cites] Curr Opin Pediatr. 2009 Apr;21(2):243-51 [19663042.001]

[Cites] Am J Gastroenterol. 2005 Jun;100(6):1340-4 [15929767.001]

[Cites] Am J Med Genet C Semin Med Genet. 2009 May 15;151C(2):136-41 [19378334.001]

[Cites] Am J Gastroenterol. 2005 Mar;100(3):652-63 [15743365.001]

[Cites] Nat Rev Gastroenterol Hepatol. 2010 Mar;7(3):163-73 [20101257.001]

[Cites] Schizophr Bull. 2008 Nov;34(6):1122-9 [18703665.001]

[Cites] Am J Gastroenterol. 2009 Sep;104(9):2250-6 [19513027.001]

[Cites] PLoS One. 2009 Dec 09;4(12):e8226 [20011045.001]

[Cites] Mayo Clin Proc. 2000 Sep;75(9):907-12 [10994826.001]

[Cites] Am J Gastroenterol. 1991 Apr;86(4):417-22 [2012042.001]

[Cites] Neurogastroenterol Motil. 2008 Dec;20(12):1291-7 [18823288.001]

[Cites] Aliment Pharmacol Ther. 2009 Sep 15;30(6):643-51 [19552631.001]

[Cites] Nat Neurosci. 2009 Mar;12(3):342-8 [19234457.001]

[Cites] Dig Dis Sci. 2004 Jun;49(6):1046-53 [15309899.001]

[Cites] Gut. 2010 Jun;59(6):775-84 [19951903.001]

[Cites] Eur J Hum Genet. 2006 Feb;14(2):159-66 [16391557.001]

[Cites] Science. 2005 Dec 16;310(5755):1817-21 [16308420.001]

[Cites] J Physiol. 2004 Jul 1;558(Pt 1):263-75 [15133062.001]

[Cites] Gut. 1986 Jan;27(1):37-40 [3949235.001]

[Cites] J Pain. 2007 Dec;8(12):962-9 [17686657.001]

[Cites] Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):17046-9 [18955703.001]

[Cites] Genes Dev. 2006 Mar 1;20(5):515-24 [16510870.001]

[Cites] Clin Gastroenterol Hepatol. 2005 Nov;3(11):1057-65 [16271334.001]

[Cites] J Neuroendocrinol. 2008 Jun;20(6):795-801 [18513204.001]

(PMID = 20585338.001).

[ISSN] 1759-5053

[Journal-full-title] Nature reviews. Gastroenterology & hepatology

[ISO-abbreviation] Nat Rev Gastroenterol Hepatol

[Language] eng

[Publication-type] Research Support, Non-U.S. Gov't; Review

[Publication-country] England

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Parental comprehension and satisfaction in informed consent in paediatric clinical trials: a prospective study on childhood leukaemia.

The authors included all parents whose consent was sought for their child to participate in the FRALLE 2000A protocol (acute lymphoblastic leukaemia) at two centres.

[MeSH-major] Health Knowledge, Attitudes, Practice. Informed Consent / psychology. Parents / psychology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Randomized Controlled Trials as Topic

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20551191.001).

[ISSN] 1468-2044

[Journal-full-title] Archives of disease in childhood

[ISO-abbreviation] Arch. Dis. Child.

[Language] eng

[Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

[Publication-country] England

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Poor prognosis in acute lymphoblastic leukemia may relate to promoter hypermethylation of cancer-related genes.

The hallmark of acute lymphoblastic leukemia (ALL) is a progressive appearance of malignant cell behavior that is triggered by the evolution of altered gene function.

The presence in individual tumors of multiple genes simultaneously methylated is an independent factor of poor prognosis in both childhood and adult ALL in terms of disease-free survival and overall survival.

[MeSH-major] DNA Methylation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17613754.001).

[ISSN] 1042-8194

[Journal-full-title] Leukemia & lymphoma

[ISO-abbreviation] Leuk. Lymphoma

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review

[Publication-country] England

[Number-of-references] 100

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Participants in the Pittsburgh EDC Study, a prospective investigation of childhood-onset type 1 DM, who underwent 2 electron beam tomographic screenings 4 years apart were selected for study (n = 222).

Genetic Alliance. consumer health - Diabetes.

Genetic Alliance. consumer health - Diabetes mellitus type 1.

MedlinePlus Health Information. consumer health - Coronary Artery Disease.

MedlinePlus Health Information. consumer health - Diabetes Type 1.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] AJR Am J Roentgenol. 2004 May;182(5):1327-32 [15100140.001]

[Cites] Clin Chem. 1972 Jun;18(6):499-502 [4337382.001]

[Cites] Clin Chem. 1973 May;19(5):476-82 [4703655.001]

[Cites] Clin Chem. 1974 Apr;20(4):470-5 [4818200.001]

[Cites] Clin Chem. 1977;23(4):666-70 [66106.001]

[Cites] Clin Chem. 1978 Jun;24(6):900-4 [207462.001]

[Cites] Diabetes. 1982 Feb;31(2):136-44 [6759229.001]

[Cites] J Pediatr. 1985 Oct;107(4):562-4 [3930679.001]

[Cites] Am J Kidney Dis. 1989 Apr;13(4):321-8 [2705450.001]

[Cites] J Am Coll Cardiol. 1990 Mar 15;15(4):827-32 [2407762.001]

[Cites] Diabetes. 1990 Sep;39(9):1116-24 [2384191.001]

[Cites] Am J Cardiol. 1993 Aug 1;72(3):247-54 [8342500.001]

[Cites] Diabetologia. 2005 Jan;48(1):41-8 [15616802.001]

[Cites] Circulation. 2005 Feb 15;111(6):747-53 [15699257.001]

[Cites] Int J Biochem Cell Biol. 2006;38(5-6):996-1003 [16271309.001]

[Cites] Diabetologia. 2006 Aug;49(8):1946-54 [16770585.001]

[Cites] Diabetes. 2006 Dec;55(12):3556-65 [17130504.001]

[Cites] Diabetes. 2000 Apr;49(4):626-32 [10871201.001]

[Cites] Diabetes. 2000 Sep;49(9):1571-8 [10969842.001]

[Cites] AJR Am J Roentgenol. 2002 Feb;178(2):497-502 [11804925.001]

[Cites] Diabetes Care. 2003 Oct;26(10):2923-8 [14514603.001]

(PMID = 17996516.001).

[ISSN] 0002-9149

[Journal-full-title] The American journal of cardiology

[ISO-abbreviation] Am. J. Cardiol.

[Language] ENG

[Grant] United States / NIDDK NIH HHS / DK / DK034818-23S1; United States / NIDDK NIH HHS / DK / R01 DK034818-23S1; United States / NIDDK NIH HHS / DK / DK34818; United States / NIDDK NIH HHS / DK / R37 DK034818; United States / NIDDK NIH HHS / DK / R01 DK034818

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] United States

[Chemical-registry-number] 0 / Cholesterol, HDL

[Other-IDs] NLM/ NIHMS34581; NLM/ PMC2206537

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Although cure rate of childhood acute lymphoblastic leukemia (ALL) has surpassed 80%, drug resistance remains a major cause of treatment failure.

Among these SNPs, the -228G>T SNP (allele frequency 9.4%) was the only one that significantly increased reporter activity in human ALL cell lines.

The -228G>T SNP altered SMARCB1 mRNA and protein levels and a positive association was found between the SMARCB1 mRNA level and both the -228 genotype and prednisolone sensitivity in CEPH cell lines.

Finally, knockdown experiments performed in human ALL cell lines confirmed that lower SMARCB1 expression increased prednisolone resistance.

[MeSH-minor] Amino Acid Sequence. Blotting, Western. Cell Line. Chromosome Mapping. Electrophoretic Mobility Shift Assay. Gene Frequency. Genotype. Humans. Lymphocytes / cytology. Lymphocytes / drug effects. Lymphocytes / metabolism. Molecular Sequence Data. Mutagenesis, Site-Directed. Polymorphism, Single Nucleotide. Prednisolone / pharmacology. Promoter Regions, Genetic / genetics. Protein Binding. RNA Interference. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Small Interfering / genetics. Sequence Alignment. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. PREDNISOLONE .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17616514.001).

[ISSN] 0964-6906

[Journal-full-title] Human molecular genetics

[ISO-abbreviation] Hum. Mol. Genet.

[Language] eng

[Grant] United States / NCI NIH HHS / CA / P30 CA21765; United States / NCI NIH HHS / CA / R01 CA51001; United States / NCI NIH HHS / CA / R01 CA78224; United States / NCI NIH HHS / CA / R37 CA36401; United States / NIGMS NIH HHS / GM / U01 GM61393; United States / NIGMS NIH HHS / GM / U01 GM61394

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Chromosomal Proteins, Non-Histone; 0 / DNA-Binding Proteins; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / SMARCB1 protein, human; 0 / Steroids; 0 / Transcription Factors; 9PHQ9Y1OLM / Prednisolone; EC 2.4.2.30 / PARP1 protein, human; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Evaluation of the P-gp pump function on leukemic cell membrane and proper application of its reversal agents with Calcein-AM and flow cytometry].

OBJECTIVE: Leukemia is the most common malignancy in children.

During the past decade, very high cure rates of childhood acute lymphoblastic leukemia (ALL) have been reported both at home and abroad.

However, the cure rates of children with acute myeloid leukemia (AML) remain low due to the multiple-drug resistance (MDR).

P-glycoprotein (P-gp) is one of the most important mechanisms of MDR for leukemia cells.

The present study aimed to evaluate the P-gp pump function on leukemia cell membrane and the effects of the combined administration of the reversal agents cyclosporin A (CSA) and verapamil (VER) through the observation of Calcein-AM (C-AM) metabolism in the cell line K562 and its multi-drug resistant subline K562/VCR.

On the other hand, significant inhibition of the efflux from the K562/VCR cell line was also noticed after the same time period of incubation with the MFIs of 2237 +/- 155, 1932 +/- 233 and 2231 +/- 147, respectively in the three groups, which was significantly higher than that of control group (1622 +/- 191, P < 0.05).

CSA, VER and CSA + VER could increase the uptake and inhibit the efflux of C-AM by K562/VCR cells, while no evident influence on those functions inside the parental cell line K562 cells was noticed.

Hazardous Substances Data Bank. VERAPAMIL HYDROCHLORIDE .

Hazardous Substances Data Bank. VINCRISTINE .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17697617.001).

[ISSN] 0578-1310

[Journal-full-title] Zhonghua er ke za zhi = Chinese journal of pediatrics

[ISO-abbreviation] Zhonghua Er Ke Za Zhi

[Language] chi

[Publication-type] English Abstract; Journal Article

[Publication-country] China

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Fluoresceins; 0 / P-Glycoprotein; 148504-34-1 / calcein AM; 5J49Q6B70F / Vincristine; CJ0O37KU29 / Verapamil; V0YM2B16TS / fluorexon

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Evaluation of a modified induction chemotherapy in children with acute lymphoblastic leukemia].

OBJECTIVE: To improve the treatment outcome of children with acute lymphoblastic leukemia (ALL), and to evaluate the efficacy and safety of a modified induction chemotherapy between the two protocols used to treat children with ALL in Shanghai Children's Medical Center.

1st, 2006, 311 patients with newly diagnosed childhood ALL, who underwent induction chemotherapy for over 10 days, were eligible for analysis.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Lymphoid / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Remission Induction / methods

Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

MedlinePlus Health Information. consumer health - Chronic Lymphocytic Leukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17697614.001).

[ISSN] 0578-1310

[Journal-full-title] Zhonghua er ke za zhi = Chinese journal of pediatrics

[ISO-abbreviation] Zhonghua Er Ke Za Zhi

[Language] chi

[Publication-type] English Abstract; Journal Article; Meta-Analysis

[Publication-country] China

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Immunosurveillance of childhood ALL: polymorphic interferon-gamma alleles are associated with age at diagnosis and clinical risk groups.

To determine whether a CA-repeat associated with differential NFkappaB-binding and IFN-gamma-expression levels may influence the incidence, manifestation and early clinical treatment response of childhood acute lymphoblastic leukemia, we performed PCR-based genotyping of 393 patients with ALL and 207 healthy controls.

[MeSH-major] Interferon-gamma / genetics. Polymorphism, Genetic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology

[MeSH-minor] Cell Lineage. Child. Child, Preschool. Female. Humans. Infant. Male. Risk Factors

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15496974.001).

[ISSN] 0887-6924

[Journal-full-title] Leukemia

[ISO-abbreviation] Leukemia

[Language] eng

[Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 82115-62-6 / Interferon-gamma

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Intravenous 6-mercaptopurine decreases salvage after relapse in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Group study CCG 1922.

PURPOSE: To compare outcomes of patients with NCI standard risk acute lymphoblastic leukemia (ALL) who relapsed after being randomized to receive either oral or intravenous 6-mercaptopurine (6MP) in the Children's Cancer Group study CCG 1922.

CONCLUSION: Treatment with intravenous 6MP during a brief period of total therapy had a significant negative impact on the prognosis in childhood ALL even though oral 6MP was used during maintenance.

[MeSH-major] 6-Mercaptopurine / administration & dosage. Antimetabolites, Antineoplastic / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Salvage Therapy

Genetic Alliance. consumer health - Childhood Cancer.

Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. MERCAPTOPURINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] Pediatr Blood Cancer. 2006 May 1;46(5):660-1 [16276523.001]

[CommentIn] Pediatr Blood Cancer. 2005 Jul;45(1):2-4 [15706584.001]

(PMID = 15481062.001).

[ISSN] 1545-5009

[Journal-full-title] Pediatric blood & cancer

[ISO-abbreviation] Pediatr Blood Cancer

[Language] eng

[Grant] United States / NCI NIH HHS / CA / CA-13539

[Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.

[Publication-country] United States

[Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; E7WED276I5 / 6-Mercaptopurine

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] The prognostic significance of CDKN2A, CDKN2B and MTAP inactivation in B-lineage acute lymphoblastic leukemia of childhood. Results of the EORTC studies 58881 and 58951.

BACKGROUND AND OBJECTIVES: Deletion and methylation of the 9p21 chromosomal region are frequent in childhood acute lymphoblastic leukemia (ALL) but the prognostic significance is controversial.

INTERPRETATION AND CONCLUSIONS: In this study of 227 cases of childhood B-lineage ALL, inactivation of CDKN2A, CDKN2B and MTAP did not influences the patients' outcome.

[MeSH-major] Gene Silencing. Neoplasm Proteins / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] Haematologica. 2006 Jul;91(7):865B [16818264.001]

(PMID = 16818274.001).

[ISSN] 1592-8721

[Journal-full-title] Haematologica

[ISO-abbreviation] Haematologica

[Language] eng

[Grant] United States / NCI NIH HHS / CA / 2U10CA11488-19; United States / NCI NIH HHS / CA / 5U10CA11488-35

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] Italy

[Chemical-registry-number] 0 / CDKN2B protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p15; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] DNA methylation and miRNA expression profiling in childhood B-cell acute lymphoblastic leukemia.

Acute lymphoblastic leukemia (ALL) is the most common cancer in children in the modern world.

A number of DNA methylation and miRNA profiling studies have investigated the role of both in childhood ALL.

[MeSH-major] DNA Methylation / physiology. Epigenesis, Genetic / physiology. High-Throughput Screening Assays / methods. MicroRNAs / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / physiopathology

Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 22122053.001).

[ISSN] 1750-192X

[Journal-full-title] Epigenomics

[ISO-abbreviation] Epigenomics

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review

[Publication-country] England

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MicroRNAs

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Establishment of testicular endocrine function impairment during childhood and puberty in boys with Klinefelter syndrome.

OBJECTIVE: To precisely characterize the chronology of testicular endocrine function impairment during childhood and adolescence in patients with Klinefelter syndrome.

However, levels of the inhibin alpha-subunit precursor Pro-alphaC were in the lowest levels of the normal range in most cases.

CONCLUSIONS: In Klinefelter syndrome, a mild Leydig cell dysfunction is present from early childhood in most cases and persists throughout puberty.

Sertoli cell function is normal until mid puberty, when a dramatic impairment is observed.

Genetic Alliance. consumer health - Klinefelter syndrome.

MedlinePlus Health Information. consumer health - Klinefelter's Syndrome.

MedlinePlus Health Information. consumer health - Puberty.

Hazardous Substances Data Bank. TESTOSTERONE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17645574.001).

[ISSN] 1365-2265

[Journal-full-title] Clinical endocrinology

[ISO-abbreviation] Clin. Endocrinol. (Oxf)

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Protein Precursors; 0 / inhibin B; 0 / inhibin-alpha subunit precursor; 3XMK78S47O / Testosterone; 57285-09-3 / Inhibins; 80497-65-0 / Anti-Mullerian Hormone; 9002-67-9 / Luteinizing Hormone

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

With this new definition the disease spectrum has broadened and ranges from intrauterine growth retardation, cerebellar hypoplasia, and death in early childhood to asymptomatic mutation carriers whose descendants are predisposed to malignancy, BMF, or pulmonary disease.

[MeSH-minor] Adult. Aged. Aging / physiology. Bone Marrow / pathology. Cell Division / genetics. Genetic Diseases, Inborn / enzymology. Genetic Diseases, Inborn / genetics. Humans. Infant, Newborn. Middle Aged. Mutation. Neoplasms / epidemiology. Neoplasms / genetics. Telomerase / genetics. Telomerase / metabolism. Telomere-Binding Proteins / genetics

Genetic Alliance. consumer health - Dyskeratosis congenita.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

[Cites] Blood. 2008 Feb 1;111(3):1128-30 [18042801.001]

[Cites] PLoS Genet. 2008 Jan;4(1):e10 [18208333.001]

[Cites] Am J Hum Genet. 2008 Feb;82(2):501-9 [18252230.001]

[Cites] Proc Natl Acad Sci U S A. 2008 Jun 10;105(23):8073-8 [18523010.001]

[Cites] Proc Natl Acad Sci U S A. 2008 Jul 22;105(29):10173-8 [18626023.001]

[Cites] Blood. 2008 Nov 1;112(9):3594-600 [18669893.001]

[Cites] Blood. 2009 Jan 8;113(2):309-16 [18931339.001]

[Cites] Blood. 2009 Jun 25;113(26):6549-57 [19282459.001]

[Cites] Nat Struct Mol Biol. 2009 Jul;16(7):740-6 [19478803.001]

[Cites] Annu Rev Genomics Hum Genet. 2009;10:45-61 [19405848.001]

[Cites] Ann N Y Acad Sci. 2009 Sep;1176:178-90 [19796246.001]

[Cites] Hum Mutat. 2009 Nov;30(11):1567-73 [19760749.001]

[Cites] PLoS One. 2009;4(11):e7926 [19936245.001]

[Cites] Science. 2009 Nov 13;326(5955):948-52 [19965504.001]

[Cites] Nat Rev Mol Cell Biol. 2010 Mar;11(3):171-81 [20125188.001]

[Cites] J Cell Biol. 2010 Mar 8;188(5):639-52 [20212315.001]

[Cites] Nucleic Acids Res. 2010 May;38(9):2955-63 [20147462.001]

[Cites] Hum Mol Genet. 2010 Apr 15;19(R1):R77-82 [20368264.001]

[Cites] Am J Hum Genet. 1994 Nov;55(5):876-82 [7977349.001]

[Cites] Nature. 1999 Dec 2;402(6761):551-5 [10591218.001]

[Cites] Proc Natl Acad Sci U S A. 1995 Apr 25;92(9):3636-41 [7731957.001]

[Cites] Science. 1996 Apr 12;272(5259):258-62 [8602509.001]

[Cites] Dev Genet. 1996;18(2):173-9 [8934879.001]

[Cites] Cell. 1997 Oct 3;91(1):25-34 [9335332.001]

[Cites] Science. 1998 Jan 16;279(5349):349-52 [9454332.001]

[Cites] Nature. 1998 Apr 9;392(6676):569-74 [9560153.001]

[Cites] Nat Genet. 1998 May;19(1):32-8 [9590285.001]

[Cites] Mol Cell Biol. 1999 Jan;19(1):567-76 [9858580.001]

[Cites] Br J Haematol. 1998 Dec;103(4):990-6 [9886310.001]

[Cites] J Exp Med. 1999 Jul 19;190(2):157-67 [10432279.001]

[Cites] N Engl J Med. 2005 Apr 7;352(14):1413-24 [15814878.001]

[Cites] Curr Mol Med. 2005 Mar;5(2):159-70 [15974869.001]

[Cites] Curr Mol Med. 2005 Mar;5(2):205-11 [15974874.001]

[Cites] Blood. 2005 Aug 15;106(4):1246-52 [15886322.001]

[Cites] Genes Dev. 2005 Sep 15;19(18):2100-10 [16166375.001]

[Cites] Br J Haematol. 2000 Sep;110(4):768-79 [11054058.001]

[Cites] Hum Mol Genet. 2001 Apr;10(7):677-85 [11257099.001]

[Cites] Blood Cells Mol Dis. 2001 Mar-Apr;27(2):353-7 [11259155.001]

[Cites] Nature. 2001 Sep 27;413(6854):432-5 [11574891.001]

[Cites] Lancet. 2002 Jun 22;359(9324):2168-70 [12090986.001]

[Cites] Nat Genet. 2003 Apr;33(4):497-501 [12640452.001]

[Cites] J Eur Acad Dermatol Venereol. 2003 Mar;17(2):216-8 [12705757.001]

[Cites] Nat Genet. 2004 May;36(5):447-9 [15098033.001]

[Cites] Annu Rev Biochem. 2004;73:177-208 [15189140.001]

[Cites] Cell. 1987 Dec 24;51(6):887-98 [3319189.001]

[Cites] Proc Natl Acad Sci U S A. 1988 Sep;85(18):6622-6 [3413114.001]

[Cites] Cell. 1989 Nov 3;59(3):521-9 [2805070.001]

[Cites] Mol Cell Biol. 1990 Feb;10(2):518-27 [2300052.001]

[Cites] Nature. 1990 May 31;345(6274):458-60 [2342578.001]

[Cites] Nature. 1990 Aug 30;346(6287):866-8 [2392154.001]

[Cites] Nature. 1991 Apr 18;350(6319):569-73 [1708110.001]

[Cites] Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10114-8 [1438199.001]

[Cites] Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):15960-4 [16247010.001]

[Cites] Proc Natl Acad Sci U S A. 2005 Nov 22;102(47):17119-24 [16284252.001]

[Cites] Mol Cell. 2006 Jan 20;21(2):249-60 [16427014.001]

[Cites] Blood. 2006 Apr 1;107(7):2680-5 [16332973.001]

[Cites] Cell Death Differ. 2006 Jun;13(6):927-34 [16543935.001]

[Cites] Nature. 2006 Sep 21;443(7109):302-7 [16943774.001]

[Cites] Semin Neurol. 2007 Apr;27(2):143-50 [17390259.001]

[Cites] N Engl J Med. 2007 Mar 29;356(13):1317-26 [17392301.001]

[Cites] Science. 2007 Mar 30;315(5820):1850-3 [17395830.001]

[Cites] Proc Natl Acad Sci U S A. 2007 May 1;104(18):7552-7 [17460043.001]

[Cites] Hum Mol Genet. 2007 Jul 1;16(13):1619-29 [17507419.001]

[Cites] Haematologica. 2007 Aug;92(8):1013-20 [17640862.001]

[Cites] Blood. 2007 Sep 1;110(5):1439-47 [17468339.001]

[Cites] Aging Cell. 2007 Oct;6(5):689-97 [17875000.001]

[Cites] Blood. 2007 Dec 15;110(13):4198-205 [17785587.001]

[Cites] Biochimie. 2008 Jan;90(1):122-30 [17825470.001]

[Cites] Mol Cell. 2007 Dec 14;28(5):773-85 [18082603.001]

(PMID = 20493861.001).

[ISSN] 1873-3468

[Journal-full-title] FEBS letters

[ISO-abbreviation] FEBS Lett.

[Language] eng

[Grant] United States / NCI NIH HHS / CA / R01 CA105312; United States / NCI NIH HHS / CA / R01 CA106995; United States / NCI NIH HHS / CA / R01 CA106995; United States / NCI NIH HHS / CA / R01 CA106995-07

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] Netherlands

[Chemical-registry-number] 0 / Telomere-Binding Proteins; 0 / shelterin, human; EC 2.7.7.49 / Telomerase

[Other-IDs] NLM/ NIHMS300709; NLM/ PMC3238451

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Apoptosis promoted by up-regulation of TFPT (TCF3 fusion partner) appears p53 independent, cell type restricted and cell density influenced.

The TFPT/FB1 gene was identified because of its involvement in childhood pre-B acute lymphoblastic leukaemia (ALL).

Although its specific function is still unclear, Tfpt has been implicated in cell proliferation and induction of programmed cell death (PCD).

Given the critical role of PCD in leukemogenesis, we have investigated the responsiveness of different cell lines to TFPT over expression and the consequent induction of PCD by proliferation kinetic analysis, immunolocalization and TUNEL assay.

We have also tested the involvement of factors implicated in cell cycle progression and apoptosis, i.e. caspases, p53, Cdc2.

Our results indicate that over expression of TFPT promotes caspase 9-dependent apoptosis, nevertheless the apoptotic cascade is engaged only in culture conditions sustaining cell proliferation and different cell lines display differential responsiveness to TFPT induced apoptosis Although p53 is a main regulator of apoptosis in mammalian cells, the Tfpt induced apoptosis appears p53-independent.

[MeSH-minor] Animals. Caspases / metabolism. Cell Count. Cell Proliferation. Enzyme Activation. Gene Expression. HeLa Cells. Humans. In Situ Nick-End Labeling. Kinetics. Mice. Models, Biological. NIH 3T3 Cells. Protein Binding. Transcription Factor 7-Like 1 Protein

Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17041757.001).

[ISSN] 1360-8185

[Journal-full-title] Apoptosis : an international journal on programmed cell death

[ISO-abbreviation] Apoptosis

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / TCF Transcription Factors; 0 / TCF7L1 protein, human; 0 / TFPT protein, human; 0 / TFPT protein, mouse; 0 / Tcf7l1 protein, mouse; 0 / Transcription Factor 7-Like 1 Protein; 0 / Tumor Suppressor Protein p53; EC 3.4.22.- / Caspases

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Simultaneous assessment of p53 and MDM2 expression in leukemic cells in response to initial prednisone therapy in children with acute lymphoblastic leukemia.

Ineffective apoptosis is one of main causes of a treatment failure in childhood acute lymphoblastic leukemia (ALL).

[MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Leukocytes, Mononuclear / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Prednisone / therapeutic use. Proto-Oncogene Proteins c-mdm2 / metabolism. Tumor Suppressor Protein p53 / metabolism

Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

MedlinePlus Health Information. consumer health - Steroids.

Hazardous Substances Data Bank. PREDNISONE .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 21290342.001).

[ISSN] 1233-9687

[Journal-full-title] Polish journal of pathology : official journal of the Polish Society of Pathologists

[ISO-abbreviation] Pol J Pathol

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Poland

[Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2; VB0R961HZT / Prednisone

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The leukemic cells were collected from 78 childhood leukemia patients admitted at Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand, in the period from July 2003 to February 2005.

There were 61 cases of acute lymphoblastic leukemia (ALL), 14 cases of acute myeloblastic leukemia (AML), and 3 cases of chronic myelocytic leukemia (CML).

Thus, curcumin treatment may provide a lead for clinical treatment of leukemia patients in the future.

[MeSH-minor] Acute Disease. Adolescent. Age Factors. Antineoplastic Agents / chemistry. Antineoplastic Agents / pharmacology. Bone Marrow / drug effects. Bone Marrow / metabolism. Bone Marrow / pathology. Cell Survival / drug effects. Child, Preschool. Female. Humans. Infant. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / blood. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology. Leukemia, Myeloid / blood. Leukemia, Myeloid / genetics. Leukemia, Myeloid / pathology. Male. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. RNA, Messenger / genetics. RNA, Messenger / isolation & purification. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction / methods. Tumor Cells, Cultured

Hazardous Substances Data Bank. CURCUMIN .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17121181.001).

[ISSN] 0253-6269

[Journal-full-title] Archives of pharmacal research

[ISO-abbreviation] Arch. Pharm. Res.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Korea (South)

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / RNA, Messenger; IT942ZTH98 / Curcumin

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] XIAP expression is post-transcriptionally upregulated in childhood ALL and is associated with glucocorticoid response in T-cell ALL.

BACKGROUND: Resistance to glucocorticoid induced apoptosis is one of the major risk factors for relapse and poor outcome in childhood acute lymphoblastic leukemia (ALL).

PROCEDURE: XIAP protein and mRNA expression were determined in leukemic blasts of 51 childhood ALL patients and normal bone marrow mononuclear cells.

RESULTS: XIAP protein but not mRNA expression was found to be highly increased in childhood ALL compared to control bone marrow mononuclear cells (MNC) (median: 3.5 vs. 0.14 ng/10(5) MNC, P < 0.0001) indicating a post-transcriptional regulation of XIAP expression.

In patients with T-cell ALL, poor prednisone response was associated with increased XIAP expression (median: 2.8 in good vs. 5.8 in poor responders; P = 0.005).

Similarly, T-cell ALL patients suffering adverse events showed higher initial XIAP levels than patients in continuous complete remission (CCR) (median: 2.7 in patients in CCR vs. 5.6 in patients suffering adverse events; P = 0.007).

CONCLUSION: In childhood ALL compared to control bone marrow, the expression of the apoptosis inhibitor XIAP is highly increased by post-transcriptional regulation.

The association with poor in vivo glucocorticoid response and outcome in T-cell ALL suggests XIAP inhibition as a promising novel approach for the treatment of resistant ALL.

[MeSH-major] Gene Expression Regulation, Leukemic. Glucocorticoids / pharmacology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. X-Linked Inhibitor of Apoptosis Protein / genetics

[MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / pharmacology. Bone Marrow Cells / pathology. Bone Marrow Examination. Child. Drug Resistance. Female. Humans. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Male. Monocytes / pathology. Pharmacogenetics. Prognosis. RNA, Messenger / analysis. Treatment Outcome. Up-Regulation

MedlinePlus Health Information. consumer health - Steroids.

Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] (c) 2010 Wiley-Liss, Inc.

(PMID = 20582956.001).

[ISSN] 1545-5017

[Journal-full-title] Pediatric blood & cancer

[ISO-abbreviation] Pediatr Blood Cancer

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Glucocorticoids; 0 / RNA, Messenger; 0 / X-Linked Inhibitor of Apoptosis Protein

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Birth weight, maternal weight and childhood leukaemia.

There is mounting evidence that childhood leukaemia is associated with high birth weight, but few studies have examined the relationship between leukaemia and other perinatal factors that influence birth weight, such as maternal weight or gestational weight gain.

This case-cohort study included 916 acute lymphocytic leukaemia (ALL) and 154 acute myeloid leukaemia (AML) cases diagnosed prior to age 10 years between 1985 and 2001 and born in New York State excluding New York City between 1978 and 2001.

These findings suggest childhood leukaemia may be related to factors influencing abnormal fetal growth patterns.

MedlinePlus Health Information. consumer health - Birth Weight.

MedlinePlus Health Information. consumer health - Leukemia.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Br J Cancer. 2002 Feb 1;86(3):356-61 [11875699.001]

[Cites] Cancer Causes Control. 2002 Feb;13(1):15-25 [11899114.001]

[Cites] Am J Epidemiol. 2002 Apr 1;155(7):603-13 [11914187.001]

[Cites] Cancer Causes Control. 2002 Sep;13(7):595-602 [12296506.001]

[Cites] Am J Obstet Gynecol. 2003 May;188(5):1372-8 [12748514.001]

[Cites] Obstet Gynecol. 2003 Jul;102(1):115-20 [12850616.001]

[Cites] Blood. 2003 Oct 1;102(7):2321-33 [12791663.001]

[Cites] J Community Health. 2003 Oct;28(5):335-46 [14535599.001]

[Cites] Am J Epidemiol. 2003 Oct 15;158(8):724-35 [14561661.001]

[Cites] Br J Cancer. 2004 Jan 12;90(1):139-45 [14710221.001]

[Cites] Int J Cancer. 2004 Jun 20;110(3):465-7 [15095317.001]

[Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jun;13(6):1057-64 [15184264.001]

[Cites] Am J Obstet Gynecol. 2004 Sep;191(3):964-8 [15467573.001]

[Cites] J Natl Cancer Inst. 2004 Oct 20;96(20):1549-56 [15494605.001]

[Cites] J Natl Cancer Inst. 1969 May;42(5):857-66 [5254278.001]

[Cites] J Natl Cancer Inst. 1971 Sep;47(3):501-9 [5157573.001]

[Cites] Int J Cancer. 1975 Jun 15;15(6):941-6 [1150348.001]

[Cites] J Natl Cancer Inst. 1976 May;56(5):879-83 [994200.001]

[Cites] Am J Epidemiol. 1984 May;119(5):788-95 [6720675.001]

[Cites] Int J Epidemiol. 1985 Dec;14(4):555-9 [3866751.001]

[Cites] Arch Dis Child. 1987 Mar;62(3):279-87 [3646026.001]

[Cites] Cancer. 1988 Aug 1;62(3):635-44 [3164642.001]

[Cites] Lancet. 1988 Dec 10;2(8624):1323-7 [2904050.001]

[Cites] Cancer Res. 1991 Jul 15;51(14):3696-701 [2065325.001]

[Cites] Cancer. 1991 Sep 15;68(6):1351-5 [1873786.001]

[Cites] Leukemia. 1994 May;8(5):856-64 [8182942.001]

[Cites] Br J Cancer. 1994 Sep;70(3):531-6 [8080742.001]

[Cites] Pediatr Hematol Oncol. 1994 Nov-Dec;11(6):587-99 [7857782.001]

[Cites] J Natl Cancer Inst. 1995 Jun 21;87(12):908-14 [7666480.001]

[Cites] Cancer Causes Control. 1996 Sep;7(5):553-9 [8877054.001]

[Cites] Ann Epidemiol. 1997 Apr;7(3):172-9 [9141639.001]

[Cites] BMJ. 1997 May 10;314(7091):1376-80 [9161309.001]

[Cites] J Natl Cancer Inst. 1997 Jul 2;89(13):939-47 [9214673.001]

[Cites] Br J Cancer. 1997;76(3):406-15 [9252212.001]

[Cites] Br J Cancer. 1997;76(9):1241-7 [9365177.001]

[Cites] J Pediatr. 1997 Nov;131(5):671-7 [9403644.001]

[Cites] J Pediatr. 1999 Feb;134(2):178-84 [9931526.001]

[Cites] Cancer Causes Control. 1999 Feb;10(1):85-94 [10334647.001]

[Cites] Br J Cancer. 1999 Jul;80(9):1483-9 [10424755.001]

[Cites] Br J Cancer. 1999 Aug;80(11):1844-51 [10468308.001]

[Cites] J Natl Cancer Inst. 1957 Dec;19(6):1087-94 [13502763.001]

[Cites] Pediatrics. 2005 Mar;115(3):e290-6 [15741354.001]

[Cites] Cancer. 2005 Apr 1;103(7):1457-67 [15712273.001]

[Cites] Cancer Causes Control. 2005 Nov;16(9):1075-83 [16184473.001]

[Cites] Eur J Endocrinol. 2005 Dec;153(6):887-94 [16322395.001]

[Cites] Pediatr Hematol Oncol. 1987;4(1):63-72 [3152913.001]

[Cites] J Natl Cancer Inst. 1999 Oct 20;91(20):1765-72 [10528028.001]

[Cites] Int J Cancer. 1999 Dec 10;83(6):712-7 [10597183.001]

[Cites] Int J Cancer. 2000 Nov 1;88(3):486-8 [11054681.001]

[Cites] Am J Epidemiol. 2001 Nov 15;154(10):889-90 [11700241.001]

[Cites] Lancet. 2001 Dec 8;358(9297):1935-40 [11747917.001]

[Cites] Coll Antropol. 2001 Dec;25(2):535-43 [11811284.001]

[Cites] Int J Epidemiol. 2001 Dec;30(6):1428-37 [11821358.001]

[Cites] Epidemiology. 1999 May;10(3):271-5 [10230837.001]

(PMID = 16736025.001).

[ISSN] 0007-0920

[Journal-full-title] British journal of cancer

[ISO-abbreviation] Br. J. Cancer

[Language] ENG

[Grant] United States / PHS HHS / / U55/CCU222012-03

[Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.

[Publication-country] England

[Other-IDs] NLM/ PMC2361297

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Analysis of human T-cell lymphotropic virus in CD25+ anaplastic large cell lymphoma in children.

Anaplastic large cell lymphoma (ALCL) is recognized as 2 distinct diseases: anaplastic lymphoma kinase (ALK)+ ALCL and ALK- ALCL.

Human T-cell lymphotropic virus (HTLV-1) is linked to the development of adult T-cell leukemia/lymphoma (ATLL), which frequently expresses CD25.

CD25 is significantly expressed in childhood ALCL.

We analyzed 33 cases of pediatric ALCL, CD25+ and CD25-, for proviral HTLV-1 DNA.

Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.

Genetic Alliance. consumer health - Lymphoma, large-cell.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Pediatrics. 2003 Aug;112(2):e136-42 [12897319.001]

[Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]

[Cites] Clin Cancer Res. 2004 Aug 15;10(16):5587-94 [15328201.001]

[Cites] Science. 1994 Mar 4;263(5151):1281-4 [8122112.001]

[Cites] Leukemia. 1994 Mar;8(3):507-9 [8127156.001]

[Cites] Hum Pathol. 1995 Jun;26(6):614-9 [7774890.001]

[Cites] Mod Pathol. 1996 Jan;9(1):63-7 [8821959.001]

[Cites] Histol Histopathol. 1997 Jul;12(3):595-601 [9225139.001]

[Cites] Am J Pathol. 1998 Mar;152(3):683-9 [9502410.001]

[Cites] Blood. 1999 Apr 15;93(8):2697-706 [10194450.001]

[Cites] Hum Pathol. 2008 Oct;39(10):1505-10 [18620733.001]

[Cites] J Acquir Immune Defic Syndr. 1999 May 1;21(1):65-71 [10235516.001]

[Cites] Blood. 1999 May 1;93(9):3088-95 [10216106.001]

[Cites] Oncogene. 2005 Jul 7;24(29):4624-33 [15735688.001]

[Cites] J Virol. 2005 Sep;79(18):11925-34 [16140768.001]

[Cites] J Invest Dermatol. 2006 Mar;126(3):575-83 [16410787.001]

[Cites] J Invest Dermatol. 2006 Mar;126(3):690-2 [16410788.001]

[Cites] Haematologica. 2006 May;91(5):596-604 [16670065.001]

[Cites] J Pediatr (Rio J). 2006 Nov-Dec;82(6):411-20 [17171202.001]

[Cites] Am J Clin Pathol. 2007 May;127(5):707-22 [17511113.001]

[Cites] Oncogene. 2007 May 28;26(25):3699-703 [17530023.001]

[Cites] Blood. 2007 Oct 1;110(7):2259-67 [17519389.001]

[Cites] Am J Clin Pathol. 2007 Nov;128(5):875-82 [17951212.001]

[Cites] Hematology Am Soc Hematol Educ Program. 2007;:285-96 [18024642.001]

[Cites] Blood. 2008 Feb 1;111(3):1560-6 [17957029.001]

[Cites] Pediatr Blood Cancer. 2008 Apr;50(4):784-7 [18022899.001]

[Cites] Blood. 2008 Jun 15;111(12):5496-504 [18385450.001]

[Cites] Cancer. 2002 Mar 15;94(6):1830-5 [11920547.001]

[Cites] Am J Hematol. 2001 Jul;67(3):172-8 [11391714.001]

[Cites] Best Pract Res Clin Haematol. 2003 Mar;16(1):117-33 [12670470.001]

[Cites] Am J Surg Pathol. 2002 Jul;26(7):823-35 [12131150.001]

[Cites] Blood. 2004 Nov 15;104(10):3355-7 [15205267.001]

(PMID = 19864230.001).

[ISSN] 1943-7722

[Journal-full-title] American journal of clinical pathology

[ISO-abbreviation] Am. J. Clin. Pathol.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / CA112217-03; United States / NCI NIH HHS / CA / CA121935-03; United States / NCI NIH HHS / CA / R01 CA112217-03; United States / NCI NIH HHS / CA / R01 CA082274-08; United States / NCI NIH HHS / CA / R01 CA082274; United States / NCI NIH HHS / CA / R01 CA121935-03; United States / NCI NIH HHS / CA / R01 CA121935

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] England

[Chemical-registry-number] 0 / DNA, Viral; 0 / IL2RA protein, human; 0 / Interleukin-2 Receptor alpha Subunit; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase

[Other-IDs] NLM/ NIHMS125676; NLM/ PMC2771325

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Nevertheless, it significantly reduces the risk of severe childhood tuberculosis and continues to be used to prevent tuberculosis in many countries.

CD3+, CD4+ and CD8+ cell counts were measured by Flow cytometry. r32kDaBCG (Ag85A-BCG) protein was used to stimulate T cells in in vitro T cell responses and interferon-gamma (IFN-gamma) cytokine levels in the supernatants were measured by ELISA.

T cell subsets were within the normal range in all subjects.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Immunol Methods. 1983 Dec 16;65(1-2):55-63 [6606682.001]

[Cites] Bull World Health Organ. 1974;51(5):473-88 [4549498.001]

[Cites] Infect Immun. 1994 Sep;62(9):3679-87 [7520418.001]

[Cites] Infect Immun. 1994 Dec;62(12):5319-26 [7525483.001]

[Cites] J Immunol. 1995 May 1;154(9):4665-74 [7722319.001]

[Cites] Indian Pediatr. 1993 Jul;30(7):899-903 [8132282.001]

[Cites] Infect Immun. 1994 Feb;62(2):726-8 [8300233.001]

[Cites] Int J Epidemiol. 1995 Oct;24(5):1042-9 [8557438.001]

[Cites] Immunology. 1996 Mar;87(3):339-42 [8778016.001]

[Cites] J Infect Dis. 1997 Nov;176(5):1351-9 [9359738.001]

[Cites] Am J Respir Crit Care Med. 1998 Mar;157(3 Pt 1):679-91 [9517576.001]

[Cites] Infect Immun. 1998 Nov;66(11):5537-42 [9784569.001]

[Cites] Infect Immun. 2000 Dec;68(12):7144-8 [11083843.001]

[Cites] Infect Immun. 2001 Apr;69(4):2714-7 [11254639.001]

[Cites] J Immunol. 2001 Nov 1;167(9):5217-25 [11673535.001]

[Cites] Science. 2002 Jan 11;295(5553):338-42 [11786644.001]

[Cites] Indian Pediatr. 2002 Jan;39(1):70-4 [11805356.001]

[Cites] Immunology. 2002 Mar;105(3):314-24 [11918693.001]

[Cites] Indian Pediatr. 2002 Apr;39(4):362-5 [11976465.001]

[Cites] Infect Immun. 2003 Jan;71(1):483-93 [12496199.001]

[Cites] Immunol Cell Biol. 2003 Feb;81(1):34-45 [12534944.001]

[Cites] Ann Clin Microbiol Antimicrob. 2004 Jun 3;3:10 [15176980.001]

[Cites] Scand J Immunol. 2004 Sep;60(3):273-7 [15320884.001]

[Cites] Tuberculosis (Edinb). 2005 Jan-Mar;85(1-2):89-93 [15687032.001]

[Cites] Tuberculosis (Edinb). 2005 Jan-Mar;85(1-2):107-14 [15687034.001]

[Cites] Indian Pediatr. 2005 Jan;42(1):36-40 [15695856.001]

[Cites] Infect Immun. 1992 Jul;60(7):2880-6 [1612754.001]

[Cites] Clin Microbiol Rev. 2005 Oct;18(4):687-702 [16223953.001]

[Cites] Thorax. 2006 Mar;61(3):247-9 [16384882.001]

[Cites] Lancet Infect Dis. 2006 Aug;6(8):522-8 [16870530.001]

[Cites] Nature. 1991 Sep 12;353(6340):180-4 [1832488.001]

[Cites] Tubercle. 1987 Mar;68(1):33-8 [3660460.001]

[Cites] Clin Diagn Lab Immunol. 1994 May;1(3):261-8 [7496960.001]

(PMID = 17555578.001).

[ISSN] 1476-8518

[Journal-full-title] Journal of immune based therapies and vaccines

[ISO-abbreviation] J Immune Based Ther Vaccines

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Other-IDs] NLM/ PMC1899498

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Expression profiling of ATP-binding cassette transporters in childhood T-cell acute lymphoblastic leukemia.

A major issue in the treatment of T-cell acute lymphoblastic leukemia (T-ALL) is resistance to chemotherapeutic drugs.

[MeSH-major] ATP-Binding Cassette Transporters / genetics. Drug Resistance, Neoplasm / genetics. Leukemia-Lymphoma, Adult T-Cell / genetics

Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16928819.001).

[ISSN] 1535-7163

[Journal-full-title] Molecular cancer therapeutics

[ISO-abbreviation] Mol. Cancer Ther.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / ABCA2 protein, human; 0 / ABCA3 protein, human; 0 / ATP-Binding Cassette Transporters; 0 / Antineoplastic Agents; 0 / Multidrug Resistance-Associated Proteins

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Childhood hematopoietic malignancies and parental use of tobacco and alcohol: the ESCALE study (SFCE).

OBJECTIVES: Investigating the role of parental smoking and maternal alcohol consumption in the etiology of childhood hematopoietic malignancies.

RESULTS: A total of 765 cases of acute leukemia (AL), 130 of Hodgkin's lymphoma (HL), 165 of non-Hodgkin's lymphoma (NHL) and 1681 controls were included.

Paternal smoking was significantly associated with childhood ALL (OR = 1.4 [1.1-1.7]), AML (OR = 1.5 [1.0-2.3]), Burkitt (OR = 2.0 [1.2-3.2]), and anaplastic large cell (OR = 3.2 [1.2-9.1]) NHL.

CONCLUSION: The results support the hypothesis that only paternal smoking, and not maternal alcohol consumption or cigarette smoking, plays a role in childhood hematopoietic malignancies.

[MeSH-minor] Burkitt Lymphoma / epidemiology. Burkitt Lymphoma / pathology. Case-Control Studies. Child. Child, Preschool. Female. France / epidemiology. Hodgkin Disease / epidemiology. Hodgkin Disease / pathology. Humans. Incidence. Leukemia, Myeloid, Acute / epidemiology. Leukemia, Myeloid, Acute / pathology. Logistic Models. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / pathology. Male. Maternal Exposure / adverse effects. Odds Ratio. Paternal Exposure / adverse effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Pregnancy. Registries / statistics & numerical data. Surveys and Questionnaires

MedlinePlus Health Information. consumer health - Alcohol.

MedlinePlus Health Information. consumer health - Smoking.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18618277.001).

[ISSN] 1573-7225

[Journal-full-title] Cancer causes & control : CCC

[ISO-abbreviation] Cancer Causes Control

[Language] eng

[Publication-type] Journal Article

[Publication-country] Netherlands

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Rearrangements of IgH, TCRD and TCRG genes as clonality marker of childhood acute lymphoblastic leukemia.

AIM: Immunoglobulin (Ig) and T-cell receptor (TCR) gene rearrangements are excellent patient-specific targets for clonality studies and monitoring of acute lymphoblastic leukemia (ALL).

RESULTS: TCRD gene rearrangements were detected in 64%, TCRG - in 45%, and IgH - in 79% of B-precursor ALL patients.

The highest incidence of oligoclonal rearrangements - 25% was shown for IgH gene in patients with B-precursor ALL.

Seven pair cases of patients with de novo leukemia and relapses were analyzed and revealed subclonal deviation in rearrangements of IgH or TCR genes during disease evolution.

CONCLUSION: We propose a panel of 13 types of rearrangements (primer pairs) sufficient for tumor cell clonality detection in 96% of patients with ALL.

[MeSH-major] Gene Rearrangement, B-Lymphocyte, Heavy Chain. Gene Rearrangement, delta-Chain T-Cell Antigen Receptor. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16404354.001).

[ISSN] 1812-9269

[Journal-full-title] Experimental oncology

[ISO-abbreviation] Exp. Oncol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Ukraine

[Chemical-registry-number] 0 / DNA Primers

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Plasma and memory B-cell kinetics in infants following a primary schedule of CRM 197-conjugated serogroup C meningococcal polysaccharide vaccine.

The induction of persistent protective levels of pathogen-specific antibody is an important goal of immunization against childhood infections.

An essential prelude to larger studies of peripheral blood B cells is an understanding of B-cell kinetics following immunization.

We measured MenC- and diphtheria-specific plasma and memory B-cell kinetics in infants receiving a CRM(197) (cross-reactive material; mutant diphtheria toxoid)-conjugated MenC vaccine at 2, 3 and 4 months of age.

Plasma cell responses were more delayed after the first dose when compared with the rapid appearance of plasma cells after the third dose.

This study provides data on B-cell kinetics following a primary schedule of immunization in young infants upon which to base further studies of the underlying cellular mechanism of humoral immunity.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Annu Rev Immunol. 2005;23:487-513 [15771579.001]

[Cites] J Immunol. 2006 Jan 1;176(1):165-72 [16365407.001]

[Cites] JAMA. 2005 Dec 21;294(23):3019-23 [16414950.001]

[Cites] J Infect Dis. 2006 Mar 15;193(6):821-8 [16479517.001]

[Cites] J Immunol. 2006 Apr 1;176(7):4042-50 [16547239.001]

[Cites] J Med Microbiol. 2006 Jul;55(Pt 7):887-96 [16772416.001]

[Cites] Immunol Rev. 2006 Jun;211:303-9 [16824137.001]

[Cites] Blood. 2006 Oct 15;108(8):2642-7 [16675705.001]

[Cites] JAMA. 2000 Jun 7;283(21):2795-801 [10838647.001]

[Cites] Eur J Immunol. 2001 Mar;31(3):939-46 [11241299.001]

[Cites] Vaccine. 2001 Nov 12;20(3-4):498-504 [11672915.001]

[Cites] Blood. 2002 Mar 15;99(6):2154-61 [11877292.001]

[Cites] J Immunol. 2002 Oct 15;169(8):4213-21 [12370351.001]

[Cites] Science. 2002 Dec 13;298(5601):2199-202 [12481138.001]

[Cites] Nature. 2003 Jan 16;421(6920):282-7 [12529646.001]

[Cites] Vaccine. 2003 Jun 1;21 Suppl 2:S35-7 [12763680.001]

[Cites] Arthritis Rheum. 2003 Aug;48(8):2146-54 [12905467.001]

[Cites] Infect Immun. 2003 Oct;71(10):5549-55 [14500473.001]

[Cites] J Immunol. 2003 Nov 15;171(10):4969-73 [14607890.001]

[Cites] J Clin Immunol. 2003 Nov;23(6):528-38 [15031640.001]

[Cites] J Immunol Methods. 2004 Mar;286(1-2):111-22 [15087226.001]

[Cites] Semin Immunol. 2004 Jun;16(3):197-203 [15130504.001]

[Cites] N Engl J Med. 2004 Jun 17;350(25):2572-81 [15201414.001]

[Cites] Lancet. 2004 Jul 24-30;364(9431):365-7 [15276396.001]

[Cites] Clin Exp Immunol. 1970 Apr;6(4):473-91 [4320164.001]

[Cites] Scand J Infect Dis. 1977;9(2):105-10 [408918.001]

[Cites] Clin Exp Immunol. 1978 Jun;32(3):443-50 [80296.001]

[Cites] J Immunol. 1979 Jun;122(6):2498-504 [312871.001]

[Cites] Clin Immunol Immunopathol. 1981 May;19(2):196-205 [6971719.001]

[Cites] J Immunol. 1982 Feb;128(2):639-43 [6976383.001]

[Cites] J Clin Immunol. 1981 Jul;1(3):174-80 [6801082.001]

[Cites] J Clin Invest. 1983 Apr;71(4):1032-40 [6339558.001]

[Cites] J Clin Invest. 1984 May;73(5):1377-84 [6609170.001]

[Cites] Eur J Immunol. 1991 Dec;21(12):2951-62 [1748148.001]

[Cites] J Exp Med. 2005 Feb 21;201(4):545-54 [15710653.001]

[Cites] Clin Infect Dis. 2006 Dec 1;43(11):1387-94 [17083009.001]

[Cites] N Engl J Med. 2007 Nov 8;357(19):1903-15 [17989383.001]

[Cites] J Immunol. 2008 Feb 15;180(4):2165-73 [18250423.001]

[Cites] Proc Natl Acad Sci U S A. 2008 Mar 25;105(12):4802-7 [18339801.001]

[Cites] Annu Rev Immunol. 1994;12:117-39 [8011279.001]

[Cites] J Clin Microbiol. 1994 Jun;32(6):1475-82 [8077392.001]

[Cites] J Virol. 1995 Mar;69(3):1895-902 [7853531.001]

[Cites] Eur J Immunol. 1996 Feb;26(2):444-8 [8617316.001]

[Cites] J Immunol. 1996 Oct 15;157(8):3357-65 [8871632.001]

[Cites] Ann N Y Acad Sci. 1996 Oct 25;797:166-76 [8993360.001]

[Cites] Nature. 1997 Jul 10;388(6638):133-4 [9217150.001]

[Cites] J Immunol. 1997 Sep 15;159(6):2652-7 [9300684.001]

[Cites] J Exp Med. 1998 Mar 16;187(6):885-95 [9500791.001]

[Cites] Immunity. 1998 Mar;8(3):363-72 [9529153.001]

[Cites] J Infect Dis. 1999 Jun;179(6):1569-72 [10228085.001]

[Cites] J Immunol. 1999 Oct 15;163(8):4315-27 [10510371.001]

[Cites] Pediatr Infect Dis J. 2004 Dec;23(12 Suppl):S274-9 [15597069.001]

[Cites] Lancet Infect Dis. 2005 Jan;5(1):21-30 [15620558.001]

[Cites] Blood. 2005 Feb 15;105(4):1614-21 [15507523.001]

[ErratumIn] Immunology. 2011 Apr;132(4):589

(PMID = 19175802.001).

[ISSN] 1365-2567

[Journal-full-title] Immunology

[ISO-abbreviation] Immunology

[Language] eng

[Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Bacterial Proteins; 0 / Meningococcal Vaccines; 0 / Vaccines, Conjugate; 0 / serogroup C meningococcal conjugate vaccine; 08VC9WC084 / CRM197 (non-toxic variant of diphtheria toxin)

[Other-IDs] NLM/ PMC2678189

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Because the symptoms of BPD in children are different from the typical symptoms in adulthood and have significant overlap with other childhood psychiatric disorders, this disorder is notoriously difficult to diagnose.

Genetic Alliance. consumer health - Anxiety.

MedlinePlus Health Information. consumer health - Anxiety.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. LITHIUM, ELEMENTAL .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16738246.001).

[ISSN] 1529-2401

[Journal-full-title] The Journal of neuroscience : the official journal of the Society for Neuroscience

[ISO-abbreviation] J. Neurosci.

[Language] ENG

[Grant] United States / NIMH NIH HHS / MH / R01 MH063266; United States / NIMH NIH HHS / MH / MH63266; United States / NIMH NIH HHS / MH / R01 MH074000-01A1; United States / NIMH NIH HHS / MH / R01 MH074000; United States / NIMH NIH HHS / MH / MH074000-01A1

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 63231-63-0 / RNA; 9FN79X2M3F / Lithium

[Other-IDs] NLM/ NIHMS197434; NLM/ PMC4205587

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Frequency of FLT3 mutations in childhood acute lymphoblastic leukemia.

FLT3 mutations are occasionally observed in acute lymphoblastic leukemia (ALL).

This study investigated the incidence of FLT3 mutations in 86 pediatric patients diagnosed with ALL and the co-presence of common RAS mutations.

[MeSH-major] Mutation / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. fms-Like Tyrosine Kinase 3 / genetics

Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Blood. 2005 Jan 15;105(2):812-20 [15374878.001]

[Cites] Blood. 1999 May 1;93(9):3074-80 [10216104.001]

[Cites] Br J Haematol. 2001 Jun;113(4):983-8 [11442493.001]

[Cites] Cancer. 2006 Feb 15;106(4):950-6 [16404744.001]

[Cites] Leukemia. 1997 Sep;11(9):1447-52 [9305596.001]

[Cites] Leukemia. 1996 Dec;10(12):1911-8 [8946930.001]

[Cites] Genes Chromosomes Cancer. 2008 Jan;47(1):26-33 [17910045.001]

[Cites] Blood. 2001 Apr 15;97(8):2434-9 [11290608.001]

[Cites] Blood. 2002 Sep 1;100(5):1532-42 [12176867.001]

[Cites] Eur J Haematol. 2006 Jul;77(1):51-6 [16573741.001]

[Cites] Genes Chromosomes Cancer. 2008 Jan;47(1):64-70 [17943971.001]

[Cites] Blood. 2004 Feb 1;103(3):1085-8 [14504097.001]

[Cites] Leukemia. 2004 Apr;18(4):685-92 [14990973.001]

[Cites] Hematology Am Soc Hematol Educ Program. 2006;:178-84 [17124058.001]

[Cites] Blood. 2005 Jun 15;105(12):4792-9 [15718420.001]

[Cites] Blood. 2004 May 1;103(9):3544-6 [14670924.001]

(PMID = 19085113.001).

[ISSN] 1559-131X

[Journal-full-title] Medical oncology (Northwood, London, England)

[ISO-abbreviation] Med. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Research on the pharmacokinetics and pharmacodynamics of L-asparaginase during its treatment of childhood acute lymphoblastic leukemia].

OBJECTIVE: To investigate the changes in the activity of Escherichia coli asparaginase (L-asp) and the concentration of asparagines (ASN) in the plasma of the acute lymphoblastic leukemia (ALL) children receiving L-asp containing chemotherapeutic protocol to explore more reasonable usage of L-asp in the treatment of childhood ALL.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacokinetics. Asparaginase / pharmacokinetics. Asparagine / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.

Hazardous Substances Data Bank. ASPARAGINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15921627.001).

[ISSN] 0253-2727

[Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

[ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi

[Language] chi

[Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] China

[Chemical-registry-number] 7006-34-0 / Asparagine; EC 3.5.1.1 / Asparaginase

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] TEL/AML 1 real-time quantitative reverse transcriptase PCR can complement minimal residual disease assessment in childhood ALL.

[MeSH-major] Neoplasm, Residual / diagnosis. Oncogene Proteins, Fusion / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Reverse Transcriptase Polymerase Chain Reaction / methods

[MeSH-minor] Child. Core Binding Factor Alpha 2 Subunit. Humans. Immunoglobulins / genetics. Prospective Studies. Receptors, Antigen, T-Cell / genetics

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15858617.001).

[ISSN] 0887-6924

[Journal-full-title] Leukemia

[ISO-abbreviation] Leukemia

[Language] eng

[Publication-type] Comparative Study; Letter; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Immunoglobulins; 0 / Oncogene Proteins, Fusion; 0 / Receptors, Antigen, T-Cell; 0 / TEL-AML1 fusion protein

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Investigation of these rodent models should complement the research from pediatric cohort studies and begin to bring us closer to understanding the role of viral respiratory tract infections in the inception of childhood asthma.

MedlinePlus Health Information. consumer health - Asthma.

MedlinePlus Health Information. consumer health - Viral Infections.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.

[Cites] Pediatr Infect Dis J. 2008 Oct;27(10 Suppl):S60-2 [18820580.001]

[Cites] Am J Respir Crit Care Med. 2008 Oct 1;178(7):667-72 [18565953.001]

[Cites] J Virol. 2009 May;83(9):4185-94 [19211758.001]

[Cites] Int J Exp Pathol. 2009 Aug;90(4):431-8 [19659901.001]

[Cites] Am J Physiol Lung Cell Mol Physiol. 2009 Sep;297(3):L401-10 [19561139.001]

[Cites] Virol J. 2009;6:122 [19671179.001]

[Cites] Proc Am Thorac Soc. 2009 Dec;6(8):693-6 [20008877.001]

[Cites] J Allergy Clin Immunol. 2010 Feb;125(2 Suppl 2):S95-102 [20176271.001]

[Cites] J Allergy Clin Immunol. 2010 Jun;125(6):1202-5 [20304476.001]

[Cites] J Allergy Clin Immunol. 2010 Jun;125(6):1212-7 [20513518.001]

[Cites] J Exp Med. 1999 Nov 15;190(10):1465-78 [10562321.001]

[Cites] J Immunol. 2000 Jun 15;164(12):6583-92 [10843718.001]

[Cites] J Clin Invest. 2002 Jul;110(2):165-75 [12122108.001]

[Cites] Pediatr Res. 2002 Sep;52(3):382-6 [12193672.001]

[Cites] J Allergy Clin Immunol. 2002 Oct;110(4):607-9 [12373269.001]

[Cites] J Exp Med. 2002 Dec 16;196(12):1645-51 [12486107.001]

[Cites] Pediatr Allergy Immunol. 2002;13 Suppl 15:38-43 [12688623.001]

[Cites] Bioinformatics. 2003 Aug 12;19(12):1461-8 [12912825.001]

[Cites] J Appl Physiol (1985). 2004 Mar;96(3):904-10 [14594863.001]

[Cites] Pediatr Res. 2004 Apr;55(4):657-65 [14711892.001]

[Cites] Am J Respir Cell Mol Biol. 2004 May;30(5):702-9 [14592927.001]

[Cites] Am J Respir Crit Care Med. 2004 Aug 1;170(3):306-12 [15130904.001]

[Cites] Lab Invest. 1988 Sep;59(3):387-96 [3411939.001]

[Cites] Am J Respir Crit Care Med. 1996 Dec;154(6 Pt 1):1834-42 [8970378.001]

[Cites] Am J Respir Crit Care Med. 1997 Jan;155(1):130-4 [9001301.001]

[Cites] Am J Respir Crit Care Med. 1999 Aug;160(2):705-10 [10430749.001]

[Cites] Pediatr Infect Dis J. 2004 Nov;23(11 Suppl):S235-45 [15577579.001]

[Cites] Nat Rev Genet. 2005 Apr;6(4):271-86 [15803197.001]

[Cites] J Virol. 2005 May;79(9):5363-73 [15827151.001]

[Cites] J Virol. 2005 Aug;79(16):10190-9 [16051812.001]

[Cites] J Allergy Clin Immunol. 2005 Aug;116(2):267-73 [16083778.001]

[Cites] J Infect Dis. 2005 Oct 1;192(7):1149-53 [16136455.001]

[Cites] J Allergy Clin Immunol. 2005 Sep;116(3):550-7 [16159623.001]

[Cites] J Allergy Clin Immunol. 2005 Sep;116(3):571-7 [16159626.001]

[Cites] Immunity. 2005 Oct;23(4):419-29 [16226507.001]

[Cites] Am J Physiol Lung Cell Mol Physiol. 2007 Jan;292(1):L85-91 [16905639.001]

[Cites] J Allergy Clin Immunol. 2007 Feb;119(2):428-33 [17196246.001]

[Cites] Eur Respir J. 2007 Apr;29(4):793-803 [17400878.001]

[Cites] Clin Exp Immunol. 2007 May;148(2):218-29 [17335559.001]

[Cites] J Allergy Clin Immunol. 2007 May;119(5):1105-10 [17353039.001]

[Cites] Proc Am Thorac Soc. 2007 Jul;4(3):221-5 [17607003.001]

[Cites] J Exp Med. 2007 Oct 29;204(11):2759-69 [17954569.001]

[Cites] Nat Med. 2008 Feb;14(2):199-204 [18246079.001]

[Cites] Am J Vet Res. 2008 Mar;69(3):416-22 [18312142.001]

[Cites] Am J Respir Crit Care Med. 2008 May 15;177(10):1111-21 [18276942.001]

[Cites] Nat Med. 2008 Jun;14(6):633-40 [18488036.001]

[Cites] Curr Drug Targets. 2008 Jun;9(6):503-10 [18537589.001]

[Cites] Clin Microbiol Rev. 2008 Jul;21(3):495-504 [18625684.001]

[Cites] Eur Respir J. 2008 Aug;32(2):314-20 [18448489.001]

[Cites] J Immunol. 2008 Aug 15;181(4):2925-32 [18684984.001]

[Cites] J Infect Dis. 2008 Nov 15;198(10):1435-43 [18828742.001]

(PMID = 21029934.001).

[ISSN] 1557-8607

[Journal-full-title] Immunology and allergy clinics of North America

[ISO-abbreviation] Immunol Allergy Clin North Am

[Language] ENG

[Grant] United States / NHLBI NIH HHS / HL / R01 HL097134; United States / NIAID NIH HHS / AI / U19 AI070503; United States / NIAID NIH HHS / AI / AI070503; United States / NHLBI NIH HHS / HL / HL097134

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review

[Publication-country] United States

[Other-IDs] NLM/ NIHMS227372; NLM/ PMC2966841

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] ZAP-70 is highly expressed in most cases of childhood pre-B cell acute lymphoblastic leukemia.

ZAP-70 is, however, expressed in adult B cell chronic lymphocytic leukemia where it correlates with a poor prognosis.

We wished to determine if ZAP-70 is also expressed in pediatric B cell malignancy.

A quantitative PCR assay for ZAP-70 expression was established and ZAP-70 expression in a range of human B cell lines was compared with expression in the Jurkat T cell line.

ZAP-70 expression was then determined in bone marrow lymphoblasts obtained from 12 patients with pre-B cell acute lymphoblastic leukemia (ALL).

ZAP-70 expression was not detected in mature B cell lines but was detected in pre-B cell lines at a level comparable to that seen in T cells.

ZAP-70 expression was strongly expressed in nine of the 12 cases of primary pre-B cell lymphoblastic leukemia.

The T cell-associated protein kinase ZAP-70 is highly expressed in pre-B lineage cells and most cases of pre-B acute lymphoblastic leukemia.

ZAP-70 expression may hold prognostic value for pre-B ALL and raises the prospect of a novel therapeutic target.

[MeSH-major] B-Lymphocytes / metabolism. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Precursor Cells, B-Lymphoid / metabolism. ZAP-70 Protein-Tyrosine Kinase / metabolism

[MeSH-minor] Adolescent. Blotting, Western. Bone Marrow Cells / metabolism. Cell Line, Transformed. Cell Line, Tumor. Child. Child, Preschool. Female. Flow Cytometry. Gene Expression. Humans. Jurkat Cells. Male. Polymerase Chain Reaction

Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18333847.001).

[ISSN] 1751-5521

[Journal-full-title] International journal of laboratory hematology

[ISO-abbreviation] Int J Lab Hematol

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase; EC 2.7.10.2 / ZAP70 protein, human

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Anteromedial plantar nodules of the heel in childhood: a variant of the normality?

Sonography showed an accumulation of tissue similar to subcutaneous cell tissue, compatible with fat.

MRI was performed in one case, showing an accumulation of fatty tissue similar to subcutaneous cell tissue.

MedlinePlus Health Information. consumer health - Foot Injuries and Disorders.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19741551.001).

[ISSN] 1473-5865

[Journal-full-title] Journal of pediatric orthopedics. Part B

[ISO-abbreviation] J Pediatr Orthop B

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Association of some rare haplotypes and genotype combinations in the MDR1 gene with childhood acute lymphoblastic leukaemia.

To investigate their possible roles in disease susceptibility and some disease characteristics we genotyped C3435T and G2677T/A polymorphisms in multidrug resistance-1 (MDR1) gene with a single base extension method and the G34A and C421A polymorphisms of the breast cancer resistance protein gene with an allelic discrimination system in 396 children with acute lymphoblastic leukaemia (ALL) and 192 control patients.

[MeSH-major] P-Glycoprotein / genetics. Polymorphism, Genetic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] Leuk Res. 2008 Aug;32(8):1173-5 [18294687.001]

(PMID = 18243305.001).

[ISSN] 0145-2126

[Journal-full-title] Leukemia research

[ISO-abbreviation] Leuk. Res.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / P-Glycoprotein